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ABSTRACT 
Master's Graduation work 123 sheets, 32 fig., 26 tab., 91 total sources. 
Keywords: Stereotactic body radiation therapy, liver metastases, Elekta 
Synergy, VMAT, DVH, ArcCHECK. 
          The aim of this work is to study the planning methodology of VMAT. the role 
of pre-treatment topometry, treatment planning, quality control plans, and delivery 
of treatment to five patients with liver metastasis in the Tomsk Regional Oncology 
Center. 
The basic constructive, technological, technical, and operational 
characteristics: Volumetric-modulated arc therapy (VMAT) is a highly sophisticated 
linear accelerator-based treatment method and allows dose rate-changing intensity 
modulation with gantry rotation. In this work, it is described our clinical experience 
with stereotactic body radiation therapy (SBRT) using a VMAT technique for five 
patients with liver metastases. 
Elekta Synergy is a high-energy linear accelerator with an intensity 
modulation function. The accelerator is designed to supply therapeutic X-ray beams 
and has a wide energy range for photon beams (6 MeV, 10 MeV). The system also 
includes: Multi-leaf collimator (MLC), iViewGT portal imaging system, XVI 
imaging system.  
To conduct topometric preparation for all patients, a Toshiba Aquilion spiral 
scanner (Toshiba, Japan) with a cut thickness of 0.5 mm was used, a reconstruction 
index of 2.0 mm; DICOM data was sent to the contouring station MonacoSim; 
contouring of critical organs and tissues, targets was carried out, planned volumes 
of exposure were determined; stage 3-D planning of the exposure program was 
carried out. Based on the obtained computed tomographic scans, a three-dimensional 
patient model was built, several treatment plans were calculated on the Monaco 
planning system. Based on the dose-volume histogram (DVH), the plans were 
evaluated, the most optimal treatment plan was selected taking into account the 
tolerant levels of radiation of critical organs and the tumor; and the verification of 
the exposure plans was carried out using the ArcCHECK dosimetric phantom (Sun 
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Nuclear Corporation, Melbourne, Florida, USA) with SNC Patient software (version 
6.7.4). In addition, to verify the position before each treatment session, the image 
system of portal XVI was used for verification. The complex of means for 
immobilizing patients during topometric preparation and the treatment consisted 
with vacuum mattress and Active Breathing Coordinator (ABC), this system consists 
of 3 main parts: ABC cart, laptop interface, mouthpiece w / flow meter and valve. 
An analysis of the results of therapy obtained during work for the five patients 
suggests a favorable outcome of treatment of liver metastasis with SBRT. 
Application area: Radiotherapy, oncology 
Cost effectiveness/significance: Liver metastases in Russia represents a 
significant clinical unmet need. Approximately, 9000 patients are diagnosed 
annually representing a significant human toll and cost burden for a health care 
system with limited resources. Despite this high prevalence, investigations of 
practice patterns and knowledge level among Russian radiation oncologists and 
medical physicists for treating this disease are lacking, since stent radiation therapy 
directed to the liver is not commonly used in Russia in the treatment of patients with 
liver metastases, because few centers are equipped for movement management. To 
achieve our objective, we carried out the measures related to the evaluation of 
patients with liver metastases and the application of the established protocol for the 
management of this disease, in order to improve the patient's quality of life. 
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INTRODUCTION 
 
 
 
National working groups in several different countries have reported their 
definitions of SBRT. The definitions of SBRT provided by the American 
Association of Physics in Medicine (AAPM) Task Group 101; the American Society 
for Therapeutic Radiology and Oncology and the American College of Radiology 
(ASTRO and ACR); the Canadian Association of Radiation Oncology—Stereotactic 
Body Radiotherapy (CARO-SBRT) and the National Radiotherapy Implementation 
Group of the UK [1-5] all agree on the following items: SBRT is (1) a method of 
external beam radiotherapy (EBRT) that (2) accurately delivers a (3) high dose of 
irradiation in (4) one or few treatment fractions to an (5) extracranial target. 
These essential components of the SBRT definition are specified in more 
detail below: 
1. SBRT can be adequately performed with either traditional linear accelerators 
equipped with suitable image-guidance technology, accelerators specifically 
adapted for SBRT or dedicated delivery systems. Additionally, the principles of 
SBRT apply for both photon and particle therapy; 
2. it is of fundamental importance that the entire SBRT workflow be systematically 
optimized and that appropriate quality assurance (QA) measures are 
implemented. From a clinical perspective, the term “accurate” covers disease 
staging; multidisciplinary discussion of the indications for SBRT; tumor site 
adjusted imaging with appropriate spatial and temporal resolution for target and 
organ at risk (OAR) definition; highly conformal treatment; image-guided patient 
setup; active or passive intrafraction motion management and follow-up 
(preferably at the treating institution). From a physics perspective, SBRT requires 
additional and more sophisticated QA procedures compared to conventional 
radiotherapy.  
SBRT developed about a decade later than SRS but was based on similar 
principles. The first paper on clinical results of SBRT was published by a research 
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group from the Karolinska Institute, Stockholm [6] and since then the technique 
has evolved dramatically and it is now one of the important cornerstones in 
modern radiation oncology. The early publication from Stockholm reported a 
local control rate of treated tumors that was much higher than expected, but a 
large number of publications confirm the high probability of local control after 
hypofractionated radiotherapy with high biological equivalent doses. 
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1 Stereotactic body radiotherapy application for liver metastases 
 
 
 
Metastatic lesions to the liver from other primary sites are not uncommon 
and can be a significant burden for patients, caregivers, and health care providers. 
Liver metastases can cause significant morbidity with pain and anorexia, adversely 
affecting health-related quality of life. In addition, more extensive liver disease can 
cause hepatic dysfunction and worsening performance status limiting systemic 
therapy and increasing mortality [7]. The most common metastatic lesion in the liver 
is from colorectal adenocarcinoma [8]. In 2017, the incidence of colorectal cancer 
(CRC) in the United States is estimated to be approximately 135,430 new cases, with 
half of these patients going on to develop liver metastasis in their lifetime [8,9]. 
Clinical series and autopsy studies have shown that as many as 40–50% of patients 
with metastatic CRC have disease confined to the liver [10], many oligometastatic 
[11], making these patients amenable for liver-directed therapies. Surgical hepatic 
metastatectomy has a long track record with 5-year survival rates of 50%–60% and 
up to 20% can achieve long-term disease-free survival in carefully selected patients 
[12,13,14]. However, only 10%–20% of liver metastases are amenable to resection, 
leaving systemic therapy as the traditional recourse for majority of patients. For 
unresectable tumors, despite advances in combination chemotherapy and targeted 
agents resulting in a doubling of median survival from approximately 10 to 
20 months, it is not without significant toxicity [15]. Chemotherapy has also been 
used to downstage lesions, potentially allowing patients to become eligible for 
surgery [16]. Since most patients with liver metastases remain ineligible for surgery, 
alternative liver-directed therapies, such as stereotactic body radiotherapy (SBRT), 
radiofrequency ablation, microwave ablation, radiolabeled microspheres, 
transarterial chemo embolization, cryoablation, and alcohol injection, have shown 
some benefit [17]. 
Historically, radiation therapy has had a limited role in the treatment of 
hepatic metastasis because of the low tolerance of the liver to radiation. A major 
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concern is the risk of radiation-induced liver disease (RILD) [18]. However, the liver 
obeys the parallel architecture model of radiobiology and the risk of RILD is 
proportional to the mean dose of radiation delivered to normal liver tissue; therefore, 
it becomes safe to treat small hepatic lesions with high doses, limiting the mean dose 
to normal liver [19]. 
In the past decade, improvements in tumor imaging, radiation therapy 
planning, delivery, and motion management, have contributed to the development 
of stereotactic body radiation therapy (SBRT). Intensification of tightly focused 
radiation to small lesions, while significantly limiting dose to the surrounding 
tissues, in either a single or limited number of dose fractions have resulted in the 
delivery of a highly biological effective dose. SBRT requires a high level of 
accuracy, and recommendations and treatment quality control guidelines have been 
established. 
In past years, several prospective and retrospective studies have reported 
effective local tumor control of hepatic metastases through stereotactic body 
radiotherapy (SBRT), with tolerable toxicity [22]. Improvements have been made in 
patient positioning and immobilization methods; image acquisition, integration, and 
transfer to radiotherapy systems; respiratory motion management; high-dose output 
and fast radiation delivery; and steep dose gradients from target lesions to 
surrounding normal tissues. Because of these advances, SBRT achieves highly 
precise and accurate radiotherapy with minimal serious toxicity [23,24]. 
Table 1 gives the results of the prospective and the largest retrospective 
cohort studies in SBRT for liver metastases. The survival of patients in 
nonrandomized SBRT-studies depends in part on how well they are selected. 
However, studies of large cohorts of patients with metastatic cancer treated with 
SBRT have reported favorable survival rates even in negatively selected patients 
who were not eligible for surgery or radiofrequency ablation (Table 1). 
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Table 1- RESULTS FROM PROSPECTIVE AND LARGE RETROSPECTIVE 
STUDIES OF SBRT FOR LIVER METASTASES 
Author; 
year 
Design 
Pts with 
liver 
metastas
es 
Frx x 
dose 
m-FU 
mts 
Local 
control 2 
years  
(%) 
Survival  
1-2 years 
(%) 
Severe 
morbidity 
Schefter 
2005 
Phase I 18 
3 x 12-
20 Gy 
NR NR NR None 
Katz 2007 Retrospect 69 
5 x 10 
Gy 
14.5 57 68, 24 None 
McCamm
on  
2009 
Retrospect 81/141a 
3 x 12 
Gy 
3 x 16 
Gy 
3 x 20 
Gy 
8.2 
89 
59 
8 
NR 
8grade >=3: 
pneumonitis
, dermatitis, 
soft tissue 
Inflammatio
n/fibrosis, 
vertebral 
fracture 
Rusthoven 
2009 
Phase I/II 47 
3 x 12-
20 Gy 
16 92 77,30 
1 grade 3: 
soft-tissue 
necrosis 
Lee 2009 Phase I 68 
6 x 4.6-
10 Gy 
11 71 (1-yr) 
79, 41 ( 
3 yrs.) 
7 grades 
>=3: 
thrombocy-
tesb, 
hepaticb, 
gastritis, 
lethargy, 
nausea 
Goodmam 
2010 
Phase I 19 
1 x 18-
30 Gy 
17 75 62, 49 
2 grades 
>=3: 
duodenal 
ulceration, 
bowel 
obstruction 
Rule 2010 Phase I 27 
3 x 10 
Gy 
5 x 10 
Gy 
5 x 12 
Gy 
20 
56 
89 
100 
90, 50 
78, 67 
75,56 
1 grade 3: 
hepaticb 
Van der 
Pool 2010 
Retrospect 20 
3 x 10-
12.5 Gy 
26 74 100, 74 
3 grade 3: 
hepaticb and 
lethargy 
Chang 
2011 
Retrospect 65 
2-3 x 20 
Gy 
55 38 (2-yr) 77, 45 
Acute: 2 
grade 3 
hepaticb 
Late: 4 
grade 3 
hepatica and 
gastritis 
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Table 1 continuation 
Comito 
2014 
Phase II 42 
4 x 12 
Gy – 
3x 25 Gy 
24 80 80, 65 None 
De Vin 
2014 
Retrospect 77/309a 
10 x 4-5 
Gy 
12 33 32 (3-yr) NR 
Fode 2015 Retrospect 225/321a 
3 x 15-
22.5 
29 LR; 13 80, 58 
Acute: 11 
grades >= 
3: hepaticb, 
nausea pain, 
gastritis, 
skin, 
deterioratio
n of 
performanc
e status 
Late: 3 
grades >= 
3: gastritis 
and skin 
Scorsetti 
2015 
Phase II 42 
3 x 25 
Gy 
24 91 81, 65 
No grade 
>= 3 
Meyer 
2016 
Phase I 14 
1 x 35-
40 Gy 
30 100 85, 78 
No grade 
>= 3 
mFU median follow-up; NR not reported; LR local recurrence in competitive risk analysis 
aMixed p atient material included other than liver metastasis patients 
bBiochemical tests  
 
For liver SBRT, integration of imaging (CT, MRI, PET-CT) is required in 
order to properly define the metastases, as is highly conformed dosimetry to further 
minimize radiation dose to healthy liver and surrounding tissues. Due to uncertainty 
of liver positioning during the breathing, the effectiveness and safety of SBRT 
depends on the accuracy to treat a moving organ. Various image-guided methods, 
the use of internal markers, breathing control and intra-fraction control of tumor 
position (Gating or Tracking) increase SBRT precision, allowing the delivery of 
cytotoxic high dose to the metastases, while maintaining whole-liver doses within 
acceptable limits [25, 26]. 
The feasibility and potential utility of SBRT in selected patients with liver 
metastases, has been evaluated with encouraging results. SBRT has resulted as a safe 
and effective treatment, with minimal toxicity and high rates of local control [27-
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34]. Therefore, it can be considered a noninvasive treatment to deliver ablative 
treatments [35,36,37]. Most of the retrospective and prospective clinical experiences 
and studies of liver metastases (using high-dose SBRT) have generally selected 
patients with a limited number of lesions. However, there are also patients with more 
than 3 liver metastases or patients with liver oligo-progression that in the course of 
their disease could be treated safely and benefit from ablative local treatments with 
sequential SBRT, thus improving their metastatic sites, decreasing morbidity and 
prolonging survival [38]. 
In the last 3 years there are international studies with important results on the 
Body Stereotactic Radiation in liver metastases and interesting conclusions about it: 
1) The study "Stereotactic body radiation therapy for liver metastasis - The linac-
based Greater Poland Cancer Centre practice" published by Fundowicz 
M, Adamczyk M, Kołodziej-Dybaś A. in April 2017. It concludes that the literature 
validation of the assumptions concerning the steps of the GPCC linac-based liver 
SBRT procedure show their potential for an effective and patient friendly 
implementation. 
2) In the study "Validation of the liver mean dose in terms of the biological effective 
dose for the prevention of radiation-induced liver damage" published in August 
2017, Hiroshi Doi, Norihisa Masai, Kenji Uemoto, Osamu Suzuki, Hiroya Shiomi, 
Daisaku Tatsumi, and Ryoong-Jin Oha refer that the actual mean doses appropriate 
for liver irradiation in modern radiotherapy techniques have not been adequately 
investigated, although SBRT is sometimes alternatively performed using 
fractionated regimens; and that is why more studies are required to define the 
optimal application of SBRT in cancer therapy and normal tissue tolerance. 
Liver metastases in Russia represents a significant clinical unmet need. 
Approximately, 9000 patients are diagnosed annually representing a significant 
human toll and cost burden for a health care system with limited resources. Despite 
this high prevalence, investigations of practice patterns and knowledge level 
among Russian radiation oncologists and medical physicists for treating this 
disease are lacking, since stent radiation therapy directed to the liver is not 
27 
 
commonly used in Russia in the treatment of patients with liver metastases, because 
few centers are equipped for movement management. 
This research work on stereotactic radiotherapy in liver metastases is 
carried out based on the current patterns of this disease in Russia; since this disease 
serves as a relevant case study among Russians due to its high prevalence in the 
population, which in itself is due to epidemiological risk factors, including a high 
rate of alcohol abuse and endemic hepatitis infection in this population. To achieve 
our objective, we carried out the measures related to the evaluation of patients with 
liver metastases and the application of the established protocol for the management 
of this disease, in order to improve the patient's quality of life. 
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2  General information 
 
 
2.1 Dose 
 
 
 
The data that are published show considerable heterogeneity in the dose-
fractionation schedules delivered. Nonetheless, there is a clear dose-response 
relationship.  
McCammon et al [39] report 3-year local control rates of 89.3% for lesions 
receiving 54-60 Gy in 3 fractions, compared to 59% (36-53.9 Gy/3 fractions), and 
8.1% (less than 36 Gy).  Similarly, Chang estimate that the dose required to achieve 
a 90% likelihood of local control at 1 year is 46-52 Gy in 3 fractions (or a BED 
(assuming an α/β of 10) of more than 75 Gy).   
A 10-fraction regimen may be useful for the palliation of larger volume 
disease and has been shown to be effective and well tolerated, even in heavily pre-
treated patients.  
However, in comparing dose regimen, it is important to note that the use of 
biological effective dose (BED) calculations when using small number of large 
fractions may not be as reliable as when used for conventionally fractionated 
radiotherapy. 
Suggested fractionations and dose distribution requirements: 
1) 40-60 Gy in 3 fractions (Alternate days) e.g. 45Gy in 3 fractions.  Prescribed to 
the prescription isodose covering at least 95% of the PTV (usually 80-95%). DMax 
within PTV<133%.  
2) 50-60 Gy in 5 fractions (Alternate days or daily) This may be used when a larger 
PTV volume is being treated in order to achieve OAR constraints (<=6cm), when 
the PTV is within 1 cm of small bowel/visceral OAR/bile duct or adjacent to chest 
wall/ribs. ≥95% of the PTV will receive the prescription dose. 
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3) 30-60 Gy in 10 fractions Consider use when target volume does not meet true 
SABR eligibility criteria (e.g. single lesion >6cm, multiple lesions where unable to 
meet 5# planning constraints or extrahepatic disease).  
10 equal fractions delivered over 2 weeks. The total dose prescribed will be 
individualized according to the effective liver volume treated as follows:  
1) 40-60 Gy if less than 30% of effective volume of liver irradiated; 
2) 35-50 Gy if between 30%-50% of effective volume of liver irradiated; 
3) 30 Gy if between 50%-70% of effective volume of liver irradiated. 
 
Table 2- LIVER DOSE CONSTRAINTS 
 
Descrip-
tion 
Constraint 
3 fractions 5 fractions 
Source End point 
Optimal 
Mand
atory 
Optimal Mandatory 
Normal 
Liver 
(Liver 
minus 
GTV) 
V10Gy - - < 70% - 3 
fractions: 
AAPM / 
Wulf et 
al/ 
Rusthove
n et al 
5 
fraction: 
ABC-07/ 
SPARC 
protocols 
Grade 3+ 
liver 
function 
dysfunctio
n/ 
radiation 
induced 
liver 
disease 
(classic or 
non-
classic) 
Mean  
liver 
dose 
- - < 13Gy 
< 
15.2Gy 
D50% < 15Gy - - - 
Dose to 
≥700cc 
< 15Gy 
< 
19.2
Gy 
- - 
 
 
2.2 Biologically Effective Dose calculation [40] 
 
 
 
When using Biologically Effective Dose (BED) calculations to estimate the 
biological dose to tumors rather than normal tissues, the main differences are that:  
a) the numerical range of α/β ratios is wider in tumors and data are lacking for many 
specific tumor types.  
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b) a repopulation correction factor should be included in the case of tumors that 
contain rapidly proliferating clonogens, for which there are several possible patterns 
of repopulation to consider.  
These requirements are now considered in turn.  
Tumor alpha/beta (α/β) Ratios  
These vary from the accepted values of 10–30 Gy for squamous cell cancers 
to much lower values of 4–5 Gy in breast cancer [35]. Other slower growing cancers, 
such as of the prostate, appear to have very small α/β ratios (0.8–2.5 Gy), although 
there remains concern that there are no established generic values for many tumor 
types and there is no predictive assay for α/β for individual tumors. Melanoma is 
another instance where very low values have been reported by some authors. For 
these reasons, it is prudent to perform multiple BED calculations, as for normal 
tissues, in order to achieve some general conclusion about which fractionation policy 
is to be recommended. If the α/β ratios are not well documented for a particular 
histological tumor type, we would recommend the use of α/β = 5, 10 and 15 Gy in 
most situations. Table 3 shows the subtle difference between schedules that are 
equivalent to 60 Gy in 30 fractions for tumor control. 
 
Table 3- CALCULATED SCHEDULES THAT ARE APPROXIMATELY 
ISOFFECTIVE TO 60 GY IN 30 FRACTIONS (SEE TEXT). 
 
α/β =5 Gy α/β =10 Gy α/β =15 Gy 
10 x 4.4 Gy 11 x 4.4 Gy 12 x 4.4 Gy 
16 x 3.25 Gy 17 x 3.25 Gy 17 x 3.25 Gy 
 
The results are calculated to the nearest whole fraction by rearrangement of 
equation to give: 
n=BED/d(1+d/(α/β))                                        (1) 
In this case, as an alternative to the approach used previously in calculations 
of normal tissue isoeffects, we calculate values of n for assumed values of d (3.25 
and 4.4 Gy respectively in table 3) and choose the final value of n to the nearest 
whole number. 
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In general, for tumors that have high α/β values, the total dose is reasonably 
predictive of local control; whereas, if the α/β values are low, the total dose and the 
fraction size together determine the outcome. 
 
2.3 Normal tissue tolerance 
 
 
 
SBRT of liver tumors is generally tolerated well. However, the esophagus, 
the stomach, the duodenum, and the large bowel should be considered in the 
selection of patients and in the treatment planning process because of their limited 
tolerance to radiation and the risk of severe adverse effects when they are exposed 
to large radiation doses. The liver tolerates large doses to relatively large volumes 
as long as a sufficient volume of liver is spared. Gastritis, gastric- or intestinal 
ulceration, chronic skin reaction, rib fracture, and hepatic failure seldom occur as 
late effects after SBRT for liver metastases. There is growing use of SBRT for 
treatment of liver metastases. The results of prospective phase I/II trials and 
retrospective cohort studies are encouraging, but we are still missing high level 
evidence to prove its efficacy. 
 
Table 4- DOSE VOLUME CONSTRAINTS FOR ORGANS AT RISK WITH 
BIOLOGIC EQUIVALENT DOSE (BED) FROM SELECTED STUDIES. 
 
Organ at risk Study 
Dose-volume 
constraint (V Gy) 
Biologic Equivalent Dose 
Liver 
(alpha/beta 3) 
Herfarth (2001) 
Wulf (2006) 
Mendez Romero 
(2006) 
V12< 30% 
V7 < 30% 
D30 < 7 Gy/ 5 Gy 
V21 < 33% 
V15< 50% 
V60 < 30% 
V29.3 < 50% 
3 fx V12.4 < 30%/V7.8<50% 
Duodenum 
(alpha/beta8) 
Wulf (2006) 
Mendez Romero 
(2006) 
Tse (2008) 
D100< 7 Gy 
D5 cc < 21 Gy 
V3 
0 < 0.5 cc 
1 fx 13.1 Gy max/3 fx 9 Gy max 
3 fx V39 < 5cc/5 fx V32 < 5cc 
V48.8 <0.5 cc 
Bowel 
(alpha/beta 8) 
Herfarth 
Wulf 
Mendez Romero 
Tse 
12 Gy max 
D100<7Gy 
D5cc <21Gy 
V30 < 0.5 
30 Gy max 
1 fx 13.1 Gy max/3 fx 9 Gy max 
1 fx V39.4 <5cc/5 fx V32 < 5cc 
V 48.8 Gy<0.5 cc 
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Table 4 continuation 
Stomach (alpha 
beta 5) 
Herfarth 
Wulf 
Mendez Romero 
Tse (2008) 
12 Gy max 
D100 < 7 Gy 
D5 cc <21 Gy 
V30 < 0.5 cc 
40.8 Gy max 
 
1 fx l6.8 Gy max/3 fx10.3 Gy 
max 
3 fx V50. 5 < 5 cc/5 fx V38.6 <5 
cc 
Spinal cord 
(alpha/beta 3) 
Shefter (2005) 
Hoyer (2006) 
Mendez Romero 
(2006) 
Tse (2008) 
18 Gy max 
18 Gy max 
15 Gy max 
V27 <0.5 cc 
54 Gy max 
54 Gy max 
3 fx 40 Gy max 5 fx 30 Gy max 
V 67.5 <0.5 cc 
 
 
2.4 Liver 
 
 
 
a) Hepatic toxicity 
The main organ at risk for irradiation of hepatic tumors is the liver itself 
[41,42]. Radiation-induced liver disease (RILD) is the main radiotherapy toxicity 
[41,43-45]. Hepatic lesions have the character of veno-occlusive diseases (VOD). 
For classical RILD, symptoms occur 4 weeks after hepatic irradiation, with an 
increased weight, a fatigue, a non-icteric ascitis and a predominant increase of 
PALK. In general, the radiologic presentation on CT scan is a hypodensity which 
disappears a few months later [46,47]. In contrast, patients with a pre-existent 
hepatopathy, as cirrhosis or viral hepatitis, may present a transaminases increase and 
a jaundice within three months following hepatic irradiation corresponding to a non-
classical post-radiation-hepatopathy. 
Hepatic functions and tumor type 
Classical data show that the whole healthy liver can receive 30 Gy per 
fractions of 2 Gy [48] and has the feature of a parallel structured organ from a 
radiobiological point of view [41,43]]. The comparison of studies should take into 
account the treatment duration and the doses per fraction according to the quadratic 
linear model [43, 49-51]. The alpha/beta ratio for healthy liver is quite low, from 1.5 
[52] to 3 [68]. Murphy et al. [45] postulates that the risk of hepatic toxicity for 
hypofractionated irradiation is overestimated in clinical practice when biological 
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normalization is omitted. While analyzing 2O3 patients treated with conformational 
RT and intra-hepatic chemotherapy, Dawson et al. [54] showed in 2002 that the 
radiation-induced liver disease (RILD) threshold dose is 30 Gy, the 5% risk of RILD 
corresponding to a 32 Gy dose (2 Gy/fraction) for patients carrying metastasis and 
28 Gy for primary hepatic tumors [55]. Andolino et al. [56] described a population 
of 60 patients treated from 2006 to 2009 for HCC associated with an A (36 patients) 
or B (24 patients) Child–Turcotte Pugh (CTP) score cirrhosis. Four patients out of 
the 8 patients with a CTP B score higher than 8, developed a hepatic failure during 
or immediately following the treatment. In this center, the indications of liver SBRT 
for this population are actually restricted to being a bridge for transplantation. For 
the other patients, it is proposed to limit the SBRT indications to patients with an A 
or B CTP score lower than or equal to 7 with a maximum tumor diameter lower than 
6 cm and one to three lesions to be treated. 
Taking these data into account, Pan et al. [43] proposed constraints for prescription 
on the liver minus GTV volume for non-uniform irradiation on healthy and 
pathological liver. For 3 fractions treatment: less than 15 Gy for metastasis, less than 
13 Gy for HCC and less than 6 Gy for HCC with a CPT equal to or lower than B. In 
terms of critical volume, 700 ml of healthy liver should receive less than 15 Gy. 
b) Biliary tract toxicity 
Few papers are dedicated to biliary complications of SBRT. Eriguchi et al. 
[57] studied 50 patients irradiated on the central biliary tract in 5 fractions for hepatic 
tumors at a total dose of 50 Gy for metastasis, 40 Gy for Child A HCC and 35 Gy 
for Child B HCC. The delineation of biliary tract was standardized and the dose 
volume histograms (DVH) of the biliary ducts were normalized for the length of the 
biliary duct irradiated. In this study, 2 grade I biliary stenosis occurred, one patient 
having received more than 20 Gy on 7 mm of the biliary duct presented a 
asymptomatic stenosis while the other one was treated twice and received more than 
80 Gy on 13 mm of the left hepatic duct. The 7 patients who received more than 
20 Gy on the gallbladder did not present any toxicity. In another article, Osmundson 
et al. [51] presented a population of 96 patients irradiated for primary or metastatic 
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hepatic lesions treated between 2006 and 2013. The central biliary system was 
defined by the authors as a 15 mm expansion of the portal veina from the splenic 
convergence to the portal bifurcation. Fifty-one patients presented biliary or hepatic 
tumors and 45 metastases. The median fraction number was 5 and 51% of patients 
received three fractions. Sixty-seven percent of patients had a Child A score, 28.1% 
a B score. Hepatobiliary grade 2 toxicities were observed for 23 patients (24%) and 
grade 3 toxicities for 18 patients (18.8%). The most frequent grade 3 toxicities were 
stenosis or biliary obstruction, the frequency being 20-fold higher for patients with 
cholangiocarcinoma (CCA). Two deaths related to biliary obstruction were 
observed, one of them for a patient with cholangiocarcinoma. The predictive factors 
in a univariate analysis were the cholangiocarcinoma and HCC histology, the 
presence of a stent during treatment and dosimetric factors. In a multivariate 
analysis, VBED10 72 > 21 cc, VBED66 > 24 cc and a mean equivalent dose > 14 Gy on 
the central biliary hepatic tract were correlated with a toxicity risk > 3, as well as 
CCA histology and the presence of the stent. The authors propose 3 fractions 
treatment with the following constraints on the central biliary 
tract: VBED10 72 < 21 cc and a VBED66 < 24 cc. [51] 
c) Stomach, duodenal and bowel toxicities 
The toxicity on the digestive tube is the one most frequently observed with 
hepatic SBRT. In general, these side effects are limited to a limited and transient 
bleeding, but some severe hemorrhages have been observed as well as perforations. 
Some data on duodenal SBRT toxicities have been identified with pancreatic tumor 
SBRT studies. In terms of radiobiology, the signification of doses is different for 
stomach (alpha/beta 5) and for bowel (alpha/beta 8). For stomach, the proposed 
constraints in various studies range from 7 to 30 Gy maximum dose with a BED of 
10.3–90 Gy [58,46,59,60,61]. Mendez Romero et al. constrained 5 cc of stomach to 
less than 21 Gy [47]. A few gastric acute toxicities have been reported. Kopek [62] 
describes an acute gastric toxicity with two grade 3 nausea for 44 patients. Herfarth 
et al. [46] also describes nausea and anorexia for 11 patients on the 37 accrued. Wulf 
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et al. [59] proposes a prophylactic IPP or anti-H2 treatment during treatment of 
hepatic metastasis closed to the stomach. 
Hoyer et al. [63] in a population of 22 patients receiving 45 Gy in 3 fractions 
delivered in 5–10 days for non-operable pancreatic tumor whose size was higher 
than 6 cm, evaluated toxicity for the duodenum. Seventy-nine percent of the patients 
presented an acute toxicity, four patients (18%) developed a severe mucositis or a 
duodenal or gastric ulceration and one of them developed a perforation. In this study, 
the median volume receiving more than 30 Gy was 136 ml. In another work, the 
same team [69] analyzed a population of 64 patients with 141 hepatic metastasis 
from colorectal carcinoma. They received 3 fractions of 15 Gy delivered in 8 days. 
Two patients who received more than 30 Gy on the duodenum presented ulcerations 
with a favorable issue with medical treatment. One grade 3 toxicity among 15 
diarrheas was reported in this study [64].  
For pancreatic tumor stereotaxis, Murphy et al. [45] have proposed a 
dosimetric model of duodenal toxicity. The duodenal delineation was specified with 
precision for 73 patients irradiated with a single 25 Gy dose 14 days after the last 
Gemcitabine treatment administration. Twelve patients presented grade 2–4 
duodenal toxicities with a median interval of 6.3 months. The predictive dosimetric 
parameters were a V15 < 9.1 cc, a V20 < 3.3 cc and a Dmax > 23 Gy. Applying the 
same prescription to 27 cholangiocarcinoma, Kopek et al. [62] observed 22% of 
gastric or duodenal ulcerations after a median delay of 6.7 months requiring 
hospitalization and blood transfusion, a duodenal stenosis for 4 patients (11%), two 
of them requiring dilatation. The probability of grade higher or equal to 2 ulceration 
was correlated to the maximal dose delivered to 1 cc of the duodenum. The 
constraint followed by this group is one cc of the duodenum to get no more than 
21 Gy in 3 fractions (V21Gy < 1 cc). 
Bae et al. [45] evaluated the abdominal or pelvic SBRT toxicities delivering 
33–60 Gy in three fractions for 202 patients. The grade 3 toxicity on the digestive 
tract was highly correlated to the V and to the overall time treatment. The severe 
bowel toxicity decreases from 50% to 4% when the V25 value is respectively higher 
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or lower than 20 ml. In the same way, the grade 3 toxicity raised from 0 to 18% for 
an overall treatment time decreased from 8 to 4 days. 
For small bowel, multiple proposals of limiting constraints have been 
defined in different studies: 12 Gy maximum, 30 Gy maximum, [60] D100 < 7 Gy 
[59], D5 < 21 Gy[66], V30 < 0.5 cc[67]. However, no major toxicity has been 
reported. 
d) Chest wall 
As observed using lung SBRT, chest wall pains and sometimes rib fracture 
are observed after liver SBRT. They are of course more frequent after treating 
tumors close to the chest wall, and for doses above 50 Gy. Andolino et al. [68] 
proposes a Dmax less than 50 Gy and that less than 5 cc of the chest wall receive 
40 Gy if these objectives are compatible with adequate tumor coverage. 
e) Less exposed organs at risk 
Dose limitation proposals have also been formulated for less exposed organs 
at risk, and observing these constraints, no clinical toxicity have been documented. 
Esophagus  
A death due to bleeding on esophageal varices, probably linked to cirrhosis 
without any other esophageal toxicity, has been observed [66].  
Some liver SBRT protocols define constraints for esophagus. Méndez 
Romero et al. limits to 5 cc the esophageal volume receiving more than 21 Gy in 3–
5 fractions. 
A maximal dose of 14 Gy is proposed by Herfarth et al., and for Tse et 
al. [61] the V30 must be less than 0.5 cc. 
Heart 
Wulf et al. [59] proposed to limit the dose delivered to the hearth to 7 Gy and 
Tse et al. [61] proposed a V40 < 0.5 cc. No cardiac toxicity has been described. 
Kidney 
Constraints proposed for the two kidneys are V15 lower than 35%, and for the 
right kidney lower than 33% [60,66]. 
Spinal cord 
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The dose has to be restricted to 18 Gy [69,60] or the V27 must be inferior to 
0.5 cc.  
f) Treatment assessments and clinical follow-up 
Acute toxicity [70] 
Radiation-induced liver disease (RILD) is defined as anicteric elevation of 
alkaline phosphatase (ALP) to greater than twice the upper limit of normal, with 
nonmalignant ascites (Classical RILD), or elevation of transaminases to more than 
5 times the upper limit of normal or pre-treatment levels (Non-classical RILD). The 
rates of RILD are notably very low in all published series (<1% in modern series). 
Childs Pugh B and Hep B/C carriage is associated with a higher incidence of RILD.  
Late toxicity 
Caution should be noted regarding late effects since several studies of liver 
SABR have observed poor survival. Only one study has durable follow up – 4.3 
years. Most others have followed up of around 16-18 months and, therefore, the 
extent of late radiation effects may be underestimated. However, the rates of high-
grade toxicity (G3 or worse) are generally low (2-5%). Reported severe late 
toxicities are rare and include GI bleeding and rib fractures. 
 
2.5  Motion management in radiation therapy 
 
 
 
These techniques have been accepted as effective radiation therapies for 
tumors that are subject to respiratory motion, as techniques that allow precise 
targeting of the tumors with prescribed radiation dosages, while reducing the dosage 
of irradiation to unaffected tissue surrounding tumors. Using respiratory motion 
management (RMM) makes it possible to reduce the irradiated area and lower the 
incidence of adverse effects in principle. However, it is necessary to bear in mind 
that, without great care, this kind of treatment poses risks that may lead to unintended 
treatment results. 
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2.5.1 RMM requirements [72] 
 
 
 
a) The treatment detailed here may only be applied when the length of respiratory 
tumor motion exceeds 10 mm without RMM being implemented. When the three-
dimensional length of motion exceeds 10 mm, the evaluation must be that ‘the length 
of respiratory-induced motion exceeds 10 mm’. For example, if the lengths of 
motion in the craniocaudal, right left, and dorsoventral directions are 9 mm, 4 mm, 
and 4 mm, respectively, the three-dimensional length is calculated as: 
  √92 + 42 + 42 = 10.6 𝑚𝑚                                       (2) 
So fulfilling the requirements of these Guidelines. The length of the respiratory-
induced tumor motion must be measured under free, unforced breathing, and 
irregularities in the respiration due to hiccups, coughs, sneezes, and deep respiration 
are to be excluded. Some institutions stipulate in the medical fee regulatory 
standards that treatment of ‘tumors whose length of respiratory motion is 10 mm or 
longer’ must be categorized as Tokkei-Shinryo (therapies covered by special 
schedules). However, the Guidelines detailed here assume that RMM is applicable 
to tumors where the length of respiratory motion exceeds 10 mm;  
b) In the treatment plans, it must be ascertained and recorded that the expansion of 
area of irradiation required to compensate for respiratory motion can be reduced 
to≤5 mm in any direction, three dimensionally. In regulations for medical treatment 
fees and institutional standards, two different expressions are used: ‘expansion of 
field of irradiation required due to respiratory motion’, and ‘expansion of area of 
irradiation required to compensate for respiratory motion’. However, the present 
guidelines use only the expression: ‘expansion of area of irradiation required to 
compensate for respiratory motion’. ‘Expansion of area of irradiation required to 
compensate for respiratory motion’ applies to both the length of the respiration-
induced tumor motion, as well as to the uncertainties related to RMM, and is 
equivalent to a part of the internal margin defined in ICRU (International 
Commission on Radiation Units and Measurements) Report 62 [71]. The three-
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dimensional direction refers to six directions: the cranio, caudal, right, left, dorso, 
and ventral directions, and the expansion of the irradiated area necessary in each 
direction must be 5 mm or less. If the expansion of area of irradiation required in 
order to compensate for respiratory motion is 5 mm or less in any one direction, 
then, where the irradiated area does not contract when compared with areas where 
RMM is not performed, it cannot be regarded as effective RMM;  
c) At every instance of irradiation treatment, it is necessary to ascertain and record 
that the tumor is included in the irradiated area determined in (b), immediately prior 
to and during the irradiation. ‘Immediately prior to the irradiation’ refers to the time 
from placing the patient on the treatment table in the room where the irradiation will 
take place until the start of the first beam of irradiation of the treatment. ‘During the 
irradiation’ refers to the time during which each treatment beam takes place. ‘A 
tumor is included in the irradiated area’ means that a tumor is included in the 
planning target volume (PTV), three-dimensionally. However, 2D confirmation is 
acceptable during the irradiation. 
When it is difficult to directly verify that the tumor is included in the 
irradiated area, it is acceptable to confirm this based on a marker in the body that 
represents the tumor positions, such as a marker in the vicinity of the tumor. In such 
cases, it is assumed that the method of predicting tumor positions based on the 
particular marker has been verified. It is necessary to verify that a tumor is included 
in the irradiated area immediately prior to the irradiation. Furthermore, it is 
recommended to verify this state, the inclusion of the tumor in the irradiated area, 
during the irradiation. (According to the description in the document for medical 
treatment fees, this verification should be performed immediately prior to the 
irradiation OR during the irradiation; however, these Guidelines specify the 
performance of the verification immediately prior to the irradiation as 
indispensable). 
 
2.5.2 Examples of measures that may be considered with RMM 
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The following six methods are described as examples of measures to include 
with RMMs in the 2008 Guidelines for Radiotherapy Planning [73]: 
a) inhalation of oxygen;  
b) abdominal compression: a method to secure a part of the abdomen by a band or 
shell, a method that uses an abdominal compression board, and others;  
c) learning of regular respiratory patterns (the metronome method); 
d) breath hold technique: active breathing control, self-respiratory cessation in deep 
inspiration; 
e) self-respiratory breath-monitoring measured at two thoraco-abdominal points; 
gating with respiration;  
f) real-time tumor-tracking: pursuing irradiation and intercepting irradiation. 
If a technique satisfies the requirements listed in the definition of RMMs, it 
may be accepted for inclusion as an RMM. However, it is generally difficult to meet 
the requirements if (i) inhalation of oxygen, or (iii) learning of regular respiratory 
patterns, is used alone.  
Measure (vi) is regarded as a ‘real-time tumor-tracking irradiation technique’, and 
techniques to pursue and intercept correspond to Real-time tumor-tracking 
irradiation techniques (i) and (ii), respectively.  
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3 Overview of equipment 
 
 
3.1 Immobilization devices 
 
 
 
Patient immobilization and control of organ motion are crucial for the 
success of SBRT in this setting. A variety of body frame systems are available, most 
relying on vacuum cushions, with or without abdominal compression [74,75]. 
Abdominal compression is a convenient mean of reducing tumor motion by 
applying a compressive plate or a breath belt during both planning CT and treatment. 
High levels of forces are required to compress the abdomen [76], and subxiphoid 
compression is advised for better breathing management, reducing craniocaudal 
liver motion to within 5 mm [77]. However, liver deformation and gross tumor 
volume positional deviation are important consequences of abdominal compression, 
necessitating rigid liver-to-liver registrations to minimize variations [78]. 
 
 
Figure 1 - Abdominal compression (BodyFIX) 
 
Motion is a major cause of artifacts in modern imaging and errors in high-
precision therapy. BodyFIX enables accurate, precise patient positioning and 
immobilization, providing the foundation for successful imaging and treatment in 
radiation therapy. 
The patented BodyFIX dual vacuum technology maximizes repositioning 
accuracy and intra-treatment patient stability by reducing both involuntary and 
voluntary patient movement. Manufactured entirely from radiotranslucent materials, 
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BodyFIX provides artifact-free image clarity with minimal beam attenuation. The 
unique cover sheet nestles around the patient and produces a uniform pressure, 
securely immobilizing the patient’s body parts. 
The immobilization system requires only one radiation therapist for first and 
daily patient set-up. The BlueBAG BodyFIX Vacuum Cushions create a 
comfortable, stable and precise mold of the patient’s position for up to six weeks. 
They can be used for different clinical set-ups and indications such as thorax, hip or 
total body. 
Whenever precise localization and targeting are required, non-invasive 
stereotactic reference frames are available for extracranial stereotaxis. 
 
 
Figure 2 - Vacuum Cushions (BlueBAG BodyFIX) 
 
3.2  Active breathing coordinator (ABC) 
 
 
 
The ABC or Active breathing coordinator system is the respiratory gating 
system used with the Elekta treatment machine. Unlike the Varian, this system uses 
a spirometer to track the patient’s actual lung volume. Consists of 3 main parts: ABC 
cart, laptop interface, mouthpiece w / flow meter and valve. 
Methods controlling breathing motion include active breathing control 
(ABC), abdominal compression, respiratory gating, and real-time tumor tracking. 
ABC involves a modified spirometer, with two pairs of flow monitors and scissor 
valves to control respiration. Activation is triggered at a predefined lung volume, 
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“freezing” all breathing motion for 15-20 s by closing both valves. ABC-assisted 
SBRT is quick, generating the smallest planning target volume by comparison. 
However, pretreatment training is required, and it may be unsuitable for some 
patients, especially those with reduced lung function [79]. 
With respiratory gating, SBRT dose is delivered only in specific phases of 
the respiratory cycle to avoid unnecessary dosing of normal tissue and underdosing 
of the target. Treatment time is longer with gating, but it is an acceptable alternative 
to ABC. 
 
                                       Figure 3 - Trolley 
 
When the button is released the balloon, valve is deflated. If the patient 
presses the button twice is one second it will send a distress signal that will show up 
on the laptop screen. 
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Figure 4 - Patient control switch: Patient presses the button during treatment and 
releases it to stop the breath hold. 
 
3.3 Linear accelerator Elekta Synergy 
 
 
 
Linear accelerator (Figure 5) equipped with imaging systems that help locate 
structures and their structures and their inter and intrasession movement to optimize 
the patient's position before treating. 
 
 
Figure 5 - Linear accelerator Elekta Synergy. 
 
It has a multilayer collimator (MLC) of 80 sheets of 1 cm wide in the 
isocenter optimized for use in IMRT. This includes a maximum displacement per 
sheet of up to 32.5 maximum per sheet of up to 32.5 cm (for large treatment fields) 
and higher primary collimators for minimizing the dose between sheets. 
Main Features: 
a) double focus plates; 
b) fields up to 40x40 cm2; 
c) rapid placement of complex irregular fields;  
d) compatibility with most planners; 
e) optimized adjustment tools: AUTOCAL.  
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AUTOCAL is an application that coordinates several field sequences with 
different conformations for quality control of the MLC (Figure 6). 
 
 
Figure 6 - AUTOCAL 
 
The method of image-guided radiotherapy in its most advanced form was 
introduced into practice by the company Elekta with the new design of linear 
accelerator Elekta Synergy™XVI and it is intended for radiotherapy departments, 
which strive to improve their radiation therapy programs. Image-guided 
radiotherapy (IGRT) adds time as the fourth dimension to conformal radiotherapy 
and its excellent spatial resolution together with the ability to reconstruct the volume 
in any direction makes it ideal for positional registration [80]. 
Elekta Synergy™XVI, and other types derived thereof - Synergy S, Infinity, 
Axesse etc. along with the modern information system Elekta MOSAIQ have a full 
range of functions to enable the provision of treatment and medical procedures for 
the benefit of the patient: 
a) precise targeting of the determined volume; 
b) excellent organ imaging; 
c) minimization of the exposure to healthy tissue. 
Elekta is continuously improving the irradiation treatment methods and 
techniques for better shaping of the radiation field based on the exact 3D size of the 
target while eliminating inaccuracies caused by physiological movements of organs 
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and any errors during the setup. To fully utilize the potential of radiotherapy and the 
treatment of oncological patients, Elekta is working with clinical partners in the 
further development of accurate, real-time image-guided radiotherapy [80]. 
Elekta Synergy™XVI was the first linear accelerator to introduce into 
practice integrated imaging that allows the visualization of targets in the same frame 
of reference as the radiation system [80]. 
Imaging methods that use one or two 2-D X-ray images are good for 
identification of bones or markers, but they cannot differentiate soft tissue, show 
details of risk organs or provide images of cross sections of the body. For this 
purpose, Elekta Synergy ™ XVI uses the kilovoltage X-ray volume imaging XVI 
with an extended perspective by the fourth dimension and displaying in real time 
[80]. 
XVI does not scan and add up individual sections together but reads and 
reconstructs the data as a total volume in a single cycle. This results in an excellent 
image quality. Accurate imaging of the XVI model can be used for any part of the 
body and produces images which are much easier to interpret for the purposes of 
radiation treatment than images from other imaging modalities. It has spatial 
resolution, which is normally associated with the MRI image, but because it uses 
kilovolt X-rays, it does not have problems with spatial distortion which is sometimes 
attributed to MRI. Similar contrast to that of the CT enables the identification of 
structures such as tumors or organs at risk without the need to resort to implanted 
markers [80]. 
The XVI model has the potential for accurate and revolutionary changes in 
the localization of tumors and critical organs in the course of radiotherapy. Excellent 
spatial resolution and integrity-submillimetre isotropic resolution and the ability to 
reconstruct the volume in any direction makes it ideal for positional registration. 
Elekta Synergy™XVI can capture a large volume of 3-D data even during a fast 
scanning cycle. This means that it can be used to capture images of the patient in the 
irradiation position immediately before the irradiation procedure is commenced. The 
movement and changes in the tumor and organs are clearly visible and the target can 
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be located using the relationship of the overall anatomy with the irradiation beam 
without the need to use markers on the skin or calibrated movements of the 
irradiation table. The full potential of the image-guided radiotherapy is reached when 
irradiation is individually adapted to each patient in accordance with anatomical 
conditions varying in time. In cooperation with clinics around the world, Elekta is 
developing integrated and specialized tools for workflows with the linear accelerator 
Elekta Synergy™XVI and with other models derived from it (Table 5) - Synergy S, 
Infinity, Axesse, thereby creating an efficient and qualified infrastructure for further 
improvements in therapeutic irradiation and of its effectiveness. Once the daily 
target is accurately defined, the application of irradiation must be executed with the 
same accuracy in the subsequent fractions. In order to make sure that this condition 
is fulfilled, Elekta fulfills all the prerequisites of beam shaping with high levels of 
customization to the target and with the view from the beam in real time [80].  
Table 5 - ELEKTA LINEAR ACCELERATORS* COMPARISON CHART 
 
Model Versa HD 
Infinity / 
Axesse 
Synergy / 
S 
Synergy 
Platform 
Precise Compact 
Years Ma-
nufactured 
2013 & 
newer 
2009 & 
newer 
2002 & 
newer 
2002 & 
newer 
1997-
2005 
2008 & 
newer 
Power 
Source 
Magnetron Magnetron 
Magnetro
n 
Magnetro
n 
Magnetro
n 
Magnetro
n 
Photon 
Energy 
Configura-
tion 
6&10/15/18 6&10/15/18 
6&10/15/
18 
6&10/15/
18 
6&10/15/
18 
6&10/15/
18 
Electron 
Energies 
Yes Yes Yes Yes Yes No 
Multi-Leaf 
Collimator 
(MLC)** 
160 Agility 
MLC (Field 
size 
40x40cm, 
leaf 
thickness-
5mm) 
80 MLC 
(Field size 
40x40cm, 
leaf 
thickness-
10mm) Opt
ional: 160 
Agility 
80 MLC 
(Field size 
40x40cm, 
leaf 
thickness-
10mm)  
80 MLC 
(Field size 
40x40cm, 
leaf 
thickness-
10mm) 
80 MLC 
(Field size 
40x40cm, 
leaf 
thickness-
10mm) 
80 MLC 
(Field size 
40x40cm, 
leaf 
thickness-
10mm) 
Portal 
Imager 
(EPID)** 
iViewGT 
(Amorphou
s Silicon) 
iViewGT 
(Amorphou
s Silicon) 
iViewGT 
(Amorpho
us 
Silicon) 
iViewGT 
(Amorpho
us 
Silicon) 
iViewGT 
(Amorpho
us 
Silicon), 
iView 
(camera 
based) 
Optional 
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Table 5 continuation 
 
Treatment 
Delivery 
3D, IMRT, 
VMAT, 
SRS/SBR, 
SRT,SABR 
3D, IMRT, 
VMAT, 
SRS/SBRT 
(Axesse) 
3D, 
IMRT, 
VMAT, 
SRS/SBRT 
(Optional) 
3D, 
IMRT, 
VMAT, 
SRS/SBRT 
(Optional) 
3D, 
IMRT, 
SRS/SBRT 
(Optional) 
3D, 
IMRT, 
SRS/SBRT 
(Optional) 
KV 
Imaging for 
IGRT** 
XVI XVI XVI N/A N/A N/A 
CBCT FOV 
50x26cm 
XVI XVI N/A N/A N/A 
VMAT Yes Yes Yes Only with 
XVI 
N/A N/A 
Treatment 
Couch 
Hexapod (6 
degrees of 
motion) 
Precise, 
Hexapod 
(optional) 
Precise Precise Precise Precise 
Pros Latest, 
cutting-
edge 
technology 
Competes 
with Varina 
True Beam 
Integrates 
VMAT, 
gating, 
CBCT 
Digital 
System 
Reliable, 
digital 
technolog
y Includes 
the XVI-
imaging 
Relatively 
inexpensi
ve in 
secondary 
market 
Many 
systems 
available 
market 
Relatively 
inexpensi
ve to 
acquire 
Some are 
dismantle
d and used 
for parts 
Good, 
budget 
system for 
internatio
nal 
markets 
Reliable 
Cons More 
expensive 
than other 
devices 
None 
available in 
the 
secondary 
market yet 
Few 
installed in 
the U.S. 
Few Does not 
include 
XVI 
componen
t Fewer 
trained 
service 
engineers 
U.S. than 
Varian 
Installatio
n costs 
can 
double the 
cost of 
equipment 
None 
available 
in the 
U.S. 
Single 
photon 
energy 
only 
*Data shown here may not be accurate and is based on equipment seen in the secondary market. 
See manufacturers for exact data.  
**Similar devices are manufactured by vendors other than the linear accelerator manufacturer.  
 
3.4 Monaco Planning System  
 
 
 
When a new Treatment Planning System (TPS) has been purchased, initial 
testing is necessary. National and international protocols describe a set of tests to 
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evaluate its image and anatomy handling, the accuracy of its calculations, the 
completeness of its reporting capabilities and its connectivity features. 
The Monaco treatment planning system combines Monte Carlo dose 
calculation accuracy with robust optimization tools to provide high-
quality radiotherapy treatment plans for three-dimensional conformal radiotherapy 
(3D CRT), intensity modulated radiotherapy (IMRT), volumetric modulated arc 
therapy (VMAT), stereotactic radiosurgery (SRS), and stereotactic body 
radiotherapy (SBRT). Recent technology advances have allowed for fast calculation 
speeds, which allow clinicians and patients to benefit from the accuracy of the Monte 
Carlo algorithm while reducing overall planning time. A collection of biological and 
physical dose-based planning tools and templates simplify the planning process and 
allow for consistent results across organizations. At the same time, multicriteria 
optimization (MCO) ensures critical organs are spared to the greatest possible degree 
while maintaining target coverage. Monaco encompasses a full suite of treatment 
modalities, including conventional radiotherapy and particle therapy, and is paving 
the way for real-time adaptive treatments with developments in magnetic 
resonance (MR)-guided radiation therapy [81]. 
Monaco 5.11 templates further increase efficiency by allowing users to 
easily import and export treatment plans, facilitating best practice sharing across 
departments and organizations (Figure 7). The ability to create multiple prescription 
plans simultaneously reduces overall planning time as well. Improved data sharing 
creates opportunities to optimize individual treatment plans. 
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Figure 7 - Monaco 5.11 
3.5  ArcCHECK 
 
 
 
ArcCHECK is the only true 4D array specifically designed for QA of today’s 
modern rotational deliveries. At its heart are over 1300 SunPoint® Diode Detectors 
providing consistent and highly sensitive measurements for all gantry angles, with 
no additional hardware required. Independent absolute dose measurements enable 
the gold standard for stringent and efficient patient plan and machine QA testing. 
 
 
Figure 8 - ArcCHECK.  
 
This phantom has the following characteristics: 
a) ease of installation (no more than 5 minutes);  
b) the sensitivity of the detectors does not depend on the angle of incidence of the 
radiation beam (information on the complete dose distribution is not lost, in contrast 
to the two-dimensional matrix, for which the loss of information at gantry angles of 
90 and 270 degrees reaches 20%);  
c) high spatial resolution, which allows verification of small fields with a high dose 
gradient (diode size 0.64 mm2, in contrast to the size of the ionization chamber 3 
mm2);  
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d) registration of both the input and output doses (which is important when assessing 
the total dose load on the patient);  
e) the ability to calibrate every three years by the user;  
f) the diode is 10 times more sensitive than the ionization chamber (more precisely, 
it measures the dose);  
g) geometric characteristics close to the patient’s body.  
 
3.5.1 An Ideal Geometry 
 
 
 
Phantoms are ideally shaped like a patient. The cylindrical design of 
ArcCHECK intentionally simulates patient geometry to better match reality. 
ArcCHECK detectors are always facing the delivery beam regardless of 
gantry angle. The detector geometry relative to the BEV remains constant. Detection 
of very small gantry angle errors is possible. In contrast, when a 2D array is 
irradiated obliquely, the geometry collapses to 1D. Even when there is no detector 
shadowing effect, significant information is lost on a 2D array, and errors up to 10° 
are missed 75% of the time. 
With ArcCHECK, gantry angle, leaf-end position, absolute dose, and time 
(4D) are measured and correlated to identify sources of error. Dose accuracy is 
improved and errors can be traced to the treatment planning system, the delivery 
system, or the imaging system. 
 
 
Figure 9 - ArcCHECK. An Ideal Geometry. 
 
3.5.2 What You See with ArcCHECK 
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ArcCHECK displays BEV dose distribution throughout the entire arc 
delivery. More data is available to perform a more thorough QA analysis. 
 
Figure 10 - ArcCHECK Measurement 
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4 PRACTICAL PART 
 
 
 
The practical part of the work was carried out on at the Tomsk Regional 
Oncology Center. For the study, 5 patients were treated with body stereotactic 
radiotherapy. Table No.6 presents the input data of the selected patients. 
 
4.1 Patient selection criteria 
 
 
 
Selection criteria for patients with liver metastases candidate to SBRT are 
controversial and a multidisciplinary board discussion is recommended. 
 
Table 6- SELECTION CRITERIA FOR SBRT.  
 
Selection criteria 
for SBRT 
Patients categories  
Suitable Cautionary Unsuitable 
Lesion number <3 4-6 >7 
Lesion diameter (cm) 1-3 >3 and ≤6 >6 
Distance from OARs (mm) >8 5-8 <5 
Liver function Child A Child B Child C 
Free liver volume (cc) >1,000 <1,000 and ≥700 <700 
 
Histopathology is not considered an inclusion or exclusion criteria. 
Similarly, age is not a selection criterion. SBRT, indeed, is a non-invasive and safe 
therapy ideal for elderly patients, who are often unsuitable for surgery. 
 Recommended selection criteria: 
a) tumors that are inoperable (a solution to hepatobiliary MDT) or are medically 
inoperative. 
b) maximum individual tumor diameter <6 cm (only speculation); 
c) life expectancy> 3 months; 
d) > 800cc normal / not involved liver; 
54 
 
e) adequate organ function: hemoglobin ≥ 9 g / dL, neutrophils ≥ 1.0×109/L, 
platelets ≥ 80 x 109/L, AST or ALT <6 x ULN, reasonable renal function. 
Recommended exclusion criteria: 
a) previous radiation therapy of the upper abdominal region, which would prevent 
partial re-irradiation of the liver due to dose limits on normal tissues; 
b) progressive extrahepatic malignant disease that cannot be controlled by surgery, 
radiation therapy, or systemic therapy; 
c) previous anticancer therapy within four weeks after SBRT; 
d) uncontrolled bleeding (disorders extrahepatic disease). 
e) patients with signs of liver failure, including hepatic encephalopathy; 
f) class C for Child-Pugh (in patients with liver dysfunction); 
g) active hepatitis; 
h) positive primary node;  
i) gross ascites; 
j) pregnant women. 
 
4.2 Planning, verification, and delivery of therapy 
 
 
 
Since September 2018, stereotactic radiotherapy for liver metastases has 
been introduced in the usual practice of the Tomsk Regional Oncology Center. 
Elekta Synergy linear accelerator is operated in this center, with the help of which 
the VMAT dose delivery technique is implemented. Elekta Synergy is a high-energy 
linear accelerator with an intensity modulation function. 
To conduct topometric preparation for all patients, a Toshiba Aquilion spiral 
scanner (Toshiba, Japan) with a cut thickness of 0.5 mm was used, a reconstruction 
index of 2.0 mm; DICOM data was sent to the contouring station MonacoSim; Later, 
contouring of critical organs and tissues, targets was carried out, planned volumes 
of exposure were determined; Stage 3-D planning of the exposure program was 
carried out. Based on the obtained computed tomographic scans, a three-dimensional 
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patient model was built, several treatment plans were calculated on the MonacoSim 
planning system. Based on the dose-volume histogram (DVH), the plans were 
evaluated, the most optimal treatment plan was selected taking into account the 
tolerant levels of radiation of critical organs and the tumor; and the verification of 
the exposure plans was carried out using the ArcCHECK dosimetric phantom (Sun 
Nuclear Corporation, Melbourne, Florida, USA) with SNC Patient software (version 
6.7.4). In addition, to verify the position before each treatment session, the image 
system of portal XVI was used for verification. The complex of means for 
immobilizing patients during topometric preparation and the treatment consisted of 
system ABC. 
Dosimetric radiation plans had the same technical calculation parameters for 
all 5 patients:  
a) photon radiation energy of 10 MV;  
b) VMAT irradiation technique;  
c) design grid 0.2 cm;  
d) maximum beamlet width 0.2 cm;  
e) maximum segment width 1 cm;  
f) Monte Carlo calculation algorithm, statistical calculation uncertainty of 0.8%. 
The dosimetric exposure plans created in the Monaco planning system were 
evaluated using dose-volume histograms (DVH) for the target and critical organs 
and based on the criteria of conformity (CI, Conformal Index) and homogeneity (HI, 
Homogeneity Index) to cover volumes the target. Further, all plans were optimized 
to achieve maximum approximation of CI and HI to unity, and according to the 
(DVH) graphs, optimization was carried out to create the most uniform and 
conformal dose distribution (equal to the value of the prescribed dose for the SBRT 
course) in terms of PTV (CTV) and so that the tolerant levels of radiation exposure 
to critical organs are not exceeded.  
To ensure that the dosimetric treatment plan in the accelerator corresponds 
to the plan presented in the planning system, the verification procedure was carried 
out in the therapeutic accelerator itself. This procedure is especially important when 
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conducting SBRT due to extremely high single doses, it allows you to see the real 
picture of the dose distribution in the patient’s body, taking into account all the 
features of the therapeutic apparatus. The specific quality control for every patient 
was performed with quality assurance system ArcCHECK. For pre-therapeutic tests, 
the dose distributions of all VMAT plans were obtained by the ArcCHECK diode 
array. Detector arrays come with their own software for calculating dosimetric 
analysis profiles or calculating the gamma index value. 
Using gamma analysis, the isodose map, taking into account the correction 
factor, in the matrix plane is compared in the DICOM format with the isodose map 
calculated on the Monaco planning system. Method allows analyzing discrepancies 
between measured and calculated by spatial and dosimetric deviations. When 
assessing dose deviation and spatial deviation, the points are compared: calculated 
(rc, Dc) and measured (rm, Dm) (Figure 11). 
 
 
 
 
 
 
Figure 11 - The dose-distance vector space shows the measured dose of Dm 
at rm and the calculated dose of Dc at rc 
For all points (rc, Dc), the difference between the calculated and measured 
doses d (i) = Dm (i) -Dc and the distance between points r (i) = rm (i) -rc are 
determined. The gamma index is calculated by the formula: 
 
𝛾(𝑖) = 𝑚𝑖𝑛√(
𝑑(𝑖)
∆𝑑
)
2
+ (
𝑟(𝑖)
∆𝑟
)
2
                                                   (3) 
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If the gamma index is less than unity, then the calculated dose is within the 
accepted criterion (for example, 3% or 2 mm) and it is considered that the dose 
distributions at this point coincide within this criterion. 
 
4.3 Results of the therapy 
 
 
 
For this study, 5 patients (2 men and 3 women) who meet the inclusion 
criteria have been taken into account; the average age of the patients is 57 years 
(ranging from 43 to 71 years); of the 5 patients, 3 were initially diagnosed with rectal 
cancer, 1 with ovarian cancer and 1 with breast cancer; however, all patients were 
taken into account for this study because they have liver metastases in common. The 
average volume of metastasis is 38.9 cc. (from 2.4 to 75.4 cc or cm3). The average 
number of fractions 3 (range from 1 to 5), the average single dose of 11 Gy (range 
from 8 to 15 Gy), the average total dose of 42 Gy (range from 39 to 45 Gy). The 
most common treatment regimen with a total dose of 45 Gy delivered over 3 
fractions. The dose was prescribed at 98,94% isodose to 100% of the target volume. 
The data of each patient are shown in Table 7. 
 
Table 7 - GENERAL DATA OF PATIENTS UNDERGOING SBRT, 
ACCORDING TO THE PATHOLOGY OF ORIGIN, NUMBER OF LIVER 
METASTASES AND TREATMENT CARRIED OUT 
 
 
Patient 
Sex 
(Male or 
Female) 
A
Age 
Pathology of 
origin 
Number of 
liver 
metastases 
Total 
Dose 
(Gy) 
Single 
Dose 
(Gy) 
BED 
α/β ratio 
(Gy) 
1 Male 46 
Rectal 
adenocarcinoma 
1 45 15 112.50 
 
2 
 
Male 
6
69 
Rectal 
adenocarcinoma 
Prostate cancer 
2 45 15 112.50 
3 Female 58 Ovarian cancer 3 42 14 100.80 
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Table 7 continuation 
 
4 
 
Female 
7
71 
Сancer of the 
rectosigmoid 
junction 
3 39 13 89.70 
5 Female 43 
Right breast 
cancer 
6 40 8 72.00 
 
Biological effective dose (BED) 
In SBRT the most used model to describe the biological effect of 
radiotherapy on the tumor cell and on healthy tissues is the linear quadratic model 
(LQM) [82, 83]. This calculates the biological effective dose (BED) using a ratio 
that considers the number of sessions, the dose absorbed per session and an α/β ratio 
that is a function of the radiosensitivity of each type of tissue. Although the model 
quadratic linear is the most widely used tool, there is controversy in favor, and 
against it being able to predict cytotoxicity at a single absorbed dose, 
underestimating tumor cell death, and overestimating the toxicity of healthy tissues. 
Consequently, it is advisable to apply protocols already in progress that are 
known about the absorbed dose schemes, the number of fractions and the values of 
absorbed dose restrictions to the risk organs. 
In SBRT treatment schemes with more than one session, such as those of the 
Radiation Therapy Oncology Group (RTOG 813), which administers 50 Gy in 5 
sessions or 60 Gy in 5 sessions, and RTOG 915, which delivers 60 Gy in 3 sessions, 
when calculating the BED of each one of them we can see that it varies between 100 
Gy and 180 Gy.   
Therefore, the α / β ratio of each tissue determines the biological effect of 
ionizing radiation on it, and it is theoretically possible to modify this effect by 
altering the fractionation. The dose received by the tumor in healthy tissue based on 
its α / β, the dose per fraction and the number of fractions is the biological effective 
dose (BED) which, according to Barendsen's basic formula [84], is equal to the total 
dose (D) multiplied by the effectiveness relative (ER): 
𝐵𝐸𝐷 = 𝑛. 𝑑. (1 +
𝑑
∝
𝛽
)                                                    (4) 
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 Where n is the number of fractions and d is the dose per fraction. 
 The table 7 shows the results of the calculations made in the five patients, 
which are developed below:  
 a) patient number 1:       3 x 15 Gy x (1+1.5) = 112.5 Gy 
 b) patient number 2:       3 x 15 Gy x (1+1.5) = 112.5 Gy 
 c) patient number 3:       3 x 14 Gy x (1+1.4) = 100.80 Gy 
 d) patient number 4:       3 x 13 Gy x (1+1.3) = 89.70 Gy 
 e) patient number 5:       5 x 8 Gy x (1+0.8) = 72.00 Gy   
            One of the characteristics of SBRT treatments, with more than one session, 
is that the BED of the treatment is equal to or greater than 100 Gy for an α/β of 10. 
However, in this study 3 of the 5 patients meet this characteristic. 
            
Table 8- RECOMMENDED DOSE CONSTRAINTS FOR THE ORGAN AT RISK 
(OARS) [12] 
 
 3 fractions 5 fractions 
coverage   
PTV 
D110%<2% 
V95%≥95% 
OAR   
Normal liver volume >700 cm3 at <15 Gy mean <15 Gy 
Stomach, duodenum, 
small bowel 
D 3 cm3 at <21 Gy D 0.5 cm3 at <32 Gy 
Both Kidneys V 15 Gy at <35% mean <12 Gy 
Spinal cord D 1 cm3 at <18 Gy D 0.5 cm3 at <28 Gy 
Heart D 1 cm3 at <30 Gy V 32 Gy at <15 cm3 
Both lungs V 12,4 Gy at <1.000 cm3 V 11,4 Gy at <1.000 cm3 
Rib D 30 cm3 at <30 Gy nil 
 
           For the five patients undergoing SBRT, the radiation exposure to critical 
organs was within the following limits (Table 8). 
           These indicators comply with international requirements for permissible 
heterogeneity of tumor irradiation. 
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4.1.1 Treatment plans 
 
 
 
For the five patients with liver metastases, treatment plans were compiled 
and verified using a high volumetric modulation of radiation intensity dose delivery 
technique in the fractionated radiation mode. Figures 12-16 show the dosimetric 
treatment plans created in the Monaco system for the 5 patients respectively, which 
fully comply with the international requirements for the degree of local tumor 
control and the degree of damage to critical organs and normal tissues.  
 
   
Figure 12- Treatment plan using VMAT to target 1 tumor in the liver. The 
orange contours represent the PTV volume, and the blue represent the 50% isodose 
lines. (Patient 1). 
 
 
 
Figure 13- Treatment plan using VMAT to target 3 tumors in the liver. The 
orange contours represent the PTV volume, and the blue represent the 50% isodose 
lines (Patient 2). 
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Figure 14- Treatment plan using VMAT to target 2 tumors in the liver. The orange 
contours represent the PTV volume, and the blue represent the 50% isodose lines 
(Patient 3). 
 
 
 
Figure 15- Treatment plan using VMAT to target 3 tumors in the liver. The orange 
contours represent the PTV volume, and the blue represent the 50% isodose lines 
(Patient 4). 
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Figure 16- Treatment plan using VMAT to target 6 tumors in the liver. The orange 
contours represent the PTV volume, and the blue represent the 50% isodose lines 
(Patient 5). 
 
In all patients, contouring of critical organs and tissues, objectives were 
performed, and planned exposure volumes were determined. 
 
4.1.2 DVH and statistics 
 
 
 
For each plan, Dose-Volume Histograms (DVH) were obtained, which allow 
a qualitative assessment of the optimality of the plan. A line of a certain color reflects 
a percentage of the volume of a certain structure that has received a specific dose. 
Histograms are presented in cumulative form for simplified perception. The figures 
16-20 below shows the DVH for each patient (Appendix 1). 
As a result of the analysis of measured and calculated dose-volume (DVH) 
histograms, conclusions were drawn about the most important structures (targets and 
critical organs) that are most exposed to radiation exposure. In this study, the 
maximum (median 49.02 Gy), mean (median 46.49 Gy)  and min (median 39.33 Gy)  
doses of PTV (represented by the purple lines); the maximum (median 48.46 Gy), 
mean (median 46.91 Gy)  and min (median 45,67 Gy) doses of GTV (represented 
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by red lines); the maximum (median 48.68 Gy), mean (median 7.88 Gy)  and min 
(median  0.19 Gy) doses of Liver margin (represented by the orange lines) and OAR 
were evaluated (such as lung sum the maximum 48.52 Gy, mean 0.49 Gy and min 
0.02 Gy was respectively; kidney right the maximum 48.24 Gy, mean 9.78 Gy and 
min 0.54 Gy was respectively; heart the maximum 41.45 Gy, mean 4.11 Gy and min 
0.59 Gy was respectively; and spinal cord the maximum 7.25 Gy, mean 1.39 Gy and 
min 0.02 was respectively); Regarding the % volume in all the structures, the mean 
value 99.84 was obtained; Whereby, the radiation doses to the OARs were within 
the constraints in all patients. Data of DVH for all 5 patients are presented in table 9 
(Appendix 1 and 2). 
According table 9 (Appendix 2)., we can conclude that the obtained 
percentage values of cold and hot zones are within acceptable limits for all created 
plans. All plans have acceptable tumor coverage (100% PTV is coated at the 
prescribed dose). 
On the other hand, the study “Patient-Specific Quality Assurance Protocol 
for Volumetric Modulated Arc Therapy using Dose Volume Histogram” carried out 
by Christopher Low, suggests that DVH should also be considered as a research tool 
that can be useful to diagnose the cause of failed plans, since it allows dose errors to 
be related to the patient's anatomy. 
This study has evidenced the integration of DVH metrics into a VMAT 
protocol to provide clinically meaningful results that complement point doses and 
gamma index measurements. 
 
4.1.3 ArCHECK QA of Dose Distribution 
 
 
 
Dynamic deliveries have become increasingly common and these techniques 
require great diligence during Quality Assurance (QA) prior to treatment. 
ArcCHECK is an accurate and efficient tool for pretreatment verification. 
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According to the quality control to verify compliance with the specified 
criteria of geometric characteristics and doses for the measured and calculated points 
of the plan, in the 5 patients, all areas meet the eligibility criteria for the location in 
question. 
Verification of the exposure plan was carried out using the ArcCHECK 
system, figures 21-25 show them for each patient (Appendix 3). 
             The cylindrical phantom ArcCHECK, allowed verifying treatment plans by 
comparing the actual plan issued by the treatment unit and calculated by the planning 
system. As a result of the comparison, two dose volume histograms were compiled, 
after the application of which it was possible to find out the dose received by one or 
the other organ. 
Gamma Analysis (verification method of volumetric modulated arc 
therapy plans) 
The quantitative analysis of dose distributions is achieved by directly 
comparing the planned isodose distributions to the measured dose planes using 
gamma analysis. 
Dose metrics are most applicable in regions of low dose-gradient, where the 
difference between calculated and measured doses at a point are determined and 
have a pass/fail criterion based on designated acceptance tolerances. In regions of 
high dose gradient, a small geometric shift could result in a large dose disparity. 
Here distance metrics are used to determine the distance between a measured dose 
point and the nearest calculated data point with a matching dose, known as distance-
to-agreement (DTA).  
According to the data on the dose distribution for VMAT for localization 
(the regions of liver metastasis), the Summary (Gamma Analysis) coincidence was 
greater than 97.7% for the 3% / 2 mm criterion. Table 10 shows the reliability results 
of the gamma analysis. 
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Table 10. RESULTS OF THE GAMMA ANALYSIS 
 
Summary (Gamma Analysis) 
Gamma criterion of 3%/2mm for the VMAT technique. 
Patient Total Points Passed Failed % Passed 
1 129 126 3 97,7 
2 390 386 4 99 
3 144 144 0          100 
4 512 512 0          100 
5 301 295 6 98 
 
The gamma index method can be summarized mathematically as follows [85]. 
DM is the dose-difference criterion (a value of 3 % is used in this study) and dM is 
the DTA criterion (a value of 2 mm is used in this study) and are evaluated for a 
single measurement point rm located at the origin of the geometric representation. 
The x and y axes represent the spatial location of the calculated distribution relative 
to the measured point rc. The vertical axis, δ, displays the difference between the 
measured dose, Dm(rm), and calculated dose, Dc(rc). An ellipsoid surface represents 
the acceptance criterion. 
The surface is defined as: 
1 =  √
𝑟2
∆𝑑𝑀
2 +
𝛿2
(∆𝐷𝑀
2 )
                                             (5) 
 
where 𝑟 = |𝑟 − 𝑟𝑚|    𝛿 = 𝐷(𝑟) − 𝐷𝑚(𝑟𝑚) is the dose difference at position rm. 
If any part of the calculated distribution surface intersects the defined ellipsoid the 
calculated point rm passes the criteria. This equation can be used to determine the 
gamma index, γ, at each point in the evaluation plan rc-rm for the point rm hence 
 
                                          𝛾 = min(Г) ∀(𝑟𝑐)                                               (6) 
where:  
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Г =  √
𝑟2
∆𝑑𝑀
2 +
𝛿2
(∆𝐷𝑀
2 )
                                             (7) 
 
And hence the pass/fail criteria can be defined by: 
γ ≤ 1, calculation passes 
γ > 1, calculation fails 
Figure 27 shows that for the 5 patients, the pass/fail criteria were defined by γ ≤ 1, 
thus, calculation passes at each point in the evaluation plan. 
 
 
Figure 27- ArcCHECK QA comparison. 
Comparison of the planning station with the verification data. 
 
The advantages of gamma index methods are that they allow for a general 
comparison that simultaneously considers dose differences and DTA, the γ values 
can be displayed as an iso-distribution and the degree to which a point fails known. 
Modern software displays dose planes and highlights the locations of failed points 
or regions and indicates whether the calculated dose is lower or greater (colder or 
hotter) than the measured dose. The quality of agreement of a beam can thus be 
assessed on either the absolute number or percentage of points that pass the criteria. 
Gamma analysis is the comparison metric used by the commercially available Sun 
Nuclear Corporation SNC Patient software. This software was used throughout this 
project to establish dosimetric % differences between five dose planes (Figure 27- 
ArcCHECK QA comparison). The department’s version of software (version 6.2.3) 
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uses an initial simplified approach, first checking if the dose difference is less than 
or equal to the prescribed 3 % criteria, and if this fails, checking if the nearest point 
on the calculated grid of the same dose is within the prescribed 2 mm criteria. In this 
case, the point is considered a passing detector point. In the event these simplified 
methods both fail to produce a passing point, Low’s method described above is used 
to find a passing point of the gamma value less than or equal to 1. If a gamma value 
is found to be greater than 1, the detector point fails. 
Quality Assurance (QA) is very important in ensuring the stable, safe and accurate 
operation of the system. In order to identify exactly the real dose into the target 
volume, it’s necessary to use dose measure and control equipment.   
To consider if the patient position set-up is the same as planned CT, cone beam CT 
was taken before the treatment by XVI systems. Information was transferred back 
to the software after the radiation oncologist completed the check, and then 
transferred again to the LINAC for treatment in the 5 patients. 
 
4.3.4 Rapid delivery of radiotherapy  
 
 
 
Finally, the radiation beam was delivered using Volumetric Arc Therapy 
(VMAT). This highly conformal, powerful x-ray beam is swept around the patient, 
into the liver tumor, without interruption. This fast delivery of radiation reduces the 
treatment time of respiratory gated treatment (Figure 28). 
 
 
Figure 28- Example of a treatment plan using VMAT to target 2 tumors in 
the liver. In this challenging case, 4 arcs were used to achieve a highly conformal 
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dose coverage around both tumors. Each arc takes less than 1-2 minutes for 
delivery. 
 
4.3.5 Effect of SBRT 
 
 
 
Effect of radiotherapy in each patient: 
a) patient No. 1 - targeted stabilization, the emergence of a new; 
b) patient No. 3 - complete regression of the target focus, the emergence of a new;  
c) patient No. 2 - stabilization by targeted lesions; 
d) patient No. 4 - stabilization by targeted foci, the emergence of new; 
e) patient No. 5 - not evaluated, not related to treatment. 
The expected response to targeted therapy is stabilization of the tumor 
process; According to the results in our patients, a local control of 100% of the cases 
was obtained, and only one patient presented complete regression. 
 
4.3.6 Medical considerations post-treatment SBRT 
 
 
 
The early side effects of SBRT to the liver include fatigue, nausea (rarely 
vomiting) and mild skin changes. These are temporary and resolve within a month 
of radiation therapy. The normal liver cells can be damaged by radiotherapy, with 
the effects seen only a few weeks after SBRT. With attention to technique in 
avoiding as much normal liver as possible, this usually shows up as mild to moderate 
abnormalities in the liver blood tests without any symptoms. The blood tests tend to 
normalize with time. For patients with underlying unhealthy liver, there is a higher 
risk of having radiation-induced liver disease that is severe enough to cause liver 
failure. Patient selection is therefore very important. 
 In the 5 patients, body stereotactic radiotherapy was satisfactory, without 
serious complications or hepatoxicity. 
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 Median follow-up - 5.9 months. The level of local control was 100%. The 
treatment was accompanied by minimal toxic effects, nausea and vomiting after an 
irradiation session - 27%, abdominal pain - 18%, fever - 9%, absence of symptoms 
46%. Toxicity of 3-4 degrees was not observed. 
 
4.3.7 Post-SBRT medical recommendations 
 
 
 
1) General clinical tests (hematological control) 7-10 days after the end of 
treatment; 
2) Observation and evaluation with an oncologist / chemotherapist, for the 
decision on the continuation of the special treatment (targeted chemotherapy); 
3) 3-8 weeks after completing treatment (depending on each patient): check 
the MRI of the liver with contrast for evaluation of the effect; 
4) Continuation of special treatment, pharmacological therapy as planned; 
5) Symptomatic treatment by a general practitioner / oncologist; 
To carry out aspect 3) it is important to take into account the following 
considerations: 
 
             3) Analysis of treatments data and results of MRI exams 
 
 
 
Liver - Segmental Anatomy on cross-sectional images (Figure 29) [86] 
Left lobe: lateral (II / III) vs medial segment (IVA / B). Extrapolate a line along the 
superior sickle ligament to the confluence of the left and middle hepatic veins in the 
IVC (blue line). 
Left versus right lobe: VAT / B vs V / VIII. Extrapolate a line from the gallbladder 
fossa superiorly along the middle hepatic vein to the IVC (red line). 
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Right lobe: anterior (V / VIII) vs posterior segment (VI / VII). Extrapolate a line 
along the right hepatic vein from the inferior IVC to the lateral hepatic margin (green 
line). 
 
 
Figure 29- Couinaud's classification of liver anatomy divides the liver into eight  
 
This figure was used to investigate which segment of the liver is affected in a total 
of 5 patients who were included in this study. 
The liver is known to be the primary target of metastasis in colorectal cancer. 
However, we do not know enough from the literature to describe the segmental 
distribution of metastatic liver lesions in colorectal cancers, prostate cancer, ovarian 
cancer, and right breast cancer. 
When the total number of metastatic lesions was evaluated, excluding segment I, the 
highest number of lesions was observed in segment VIII. The liver segments with 
the highest number of metastatic lesions were, respectively, VI, VII and VIII. In this 
case, the least number of metastatic lesions was observed in segment IV (Appendix 
4). 
This analysis concludes that liver metastases are more common in the right lobe than 
in the left lobe in this study. 
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           5   FINANCIAL MANAGEMENT, RESOURCE EFFICIENCY AND 
RESOURCE CONSERVATION 
 
 
 5.1 Pre-project analysis 
 
 
 
         At present, the prospect of scientific research is determined not so much by the 
scale of the discovery, which is difficult to assess at the first stages of the life cycle 
of a high-tech and resource-efficient product, but rather the commercial value of 
development. Evaluation of the commercial value of the development is a 
prerequisite in the search for funding sources for scientific research and 
commercialization of its results. This is important for developers who need to 
represent the state and prospects of ongoing research.  
          The objective of this work is to carry out the planning, verification and 
administration of the Stereotactic Body Radiation Therapy (SBRT) treatment to five 
patients of the Tomsk Regional Oncology Center with a diagnosed liver metastases, 
as well as an analysis of the results of the treatment with conclusions about the 
prospects for greater use of this method in the treatment of liver metastases in Tomsk 
Regional Oncology Center. The area is medicine. The sphere is radiotherapy, 
treatment of malignant tumor processes. The final consumer is the oncology centers 
and departments. Studies have shown a significant advantage of the SBRT in liver 
metastases. 
 
5.2 Ishikawa Chart 
 
 
 
The Ishikawa cause-effect diagram (Cause-and-Effect-Diagram) is a 
graphical method for the analysis and formation of cause-effect relationships, a tool 
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for the systematic determination of the causes of a problem and subsequent graphical 
presentation. The diagram created as part of this work is presented in Figure 30. 
 
 
 
  
  
 
  
  
  
 
 
 Figure 30- Cause and effect diagram of Ishikawa.  
 
The Ishikawa cause-effect diagram consists of four main areas: 
a) staff; 
b) equipment; 
c) methods; 
d) materials. 
Each area contains factors influencing the object of analysis. Table 12 
provides a description of the chart with suggested solutions to the problems. Each of 
the selected factors can affect the outcome of the study and treatment, so that their 
decision will provide a positive result, both within the framework of this work, and 
for future studies. 
 
Table 12 - DESCRIPTION OF THE ISHIKAWA DIAGRAM. 
   
Area Factors Problem Decision 
Staff Oncologists Fatigue To prevent unnecessary fatigue is possible to either 
connect additional oncologists, or break working 
hours into shifts. 
Medical 
Physicists 
Lack of 
qualifications 
To solve the problem, it is possible to either send 
staff to receive additional education or organize 
advanced training courses directly on the basis of 
Fatigue 
Positive 
treatment 
result 
Staff 
Oncologist 
An insufficient amount 
Service staff 
Equipment 
computer 
Outdated software 
Malfunction 
Accelerator 
Work time overload 
Verification Devices 
insufficient amount 
Breakage 
No guarantee 
Methods 
Repair Procedure 
Not compliant with protocols 
Planning Procedure 
 
Mismatch with criteria 
Verification 
Materials 
Small number of specialists 
Lack of supplies 
Immobilization 
Repairs 
Long 
delive
ry 
parts 
Medical 
physicist 
Not enough 
qualifications 
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the LLP. You can also hire more qualified 
professionals to transfer experience. 
Service 
staff 
Lack of 
quantity 
The only solution is to recruit additional staff 
Equipment computer Outdated 
software 
As a solution to this problem, you can either 
contact the software provider or switch to using 
another, alternative software package. 
Verification 
Devices 
Lack of 
quantity or 
breakdown 
It is necessary to purchase additional units of 
equipment, as well as find out the most vulnerable 
elements and pre-order components in case of 
unexpected breakdown. 
Accelerator Malfunction 
or overload 
It is necessary to clearly follow the instructions for 
use and in time to carry out the necessary 
procedures for inspection and health checks, as 
well as plan treatment taking into account the 
maximum load on the system. 
Methods Repair 
Procedure 
No guarantee It is necessary during the time to carry out the 
necessary procedures for examining and verifying 
the operability of equipment, as well as use the 
services of only certified specialists to maintain 
warranty service. 
Verification Mismatch with 
criteria 
It is necessary to re-carry out planning until all 
requirements are met. 
Planning Protocol 
mismatch 
It is necessary to draw up a clear documentation of 
the criteria with which all plans will have to check 
and follow this instruction for each patient. 
 
5.3 SWOT analysis 
 
 
 
SWOT - Strengths Weaknesses Opportunities Threats - is a comprehensive 
analysis of a research project. The purpose of its implementation is to identify the 
strengths and weaknesses of the project, as well as an understanding of the 
opportunities and threats that affect the process of performing work. The first stage 
of the SWOT analysis is presented in table 13. 
 
 
 
Table 12 continuation 
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Table 13 - FIRST PHASE SWOT ANALYSIS 
 Strengths of a 
research project: 
C1. Shipping Modern 
treatment 
C2. Use 
hypofractionation 
C3. High Performance 
Center 
C4. High effectiveness 
of treatment 
C5. High Qualification 
Involved Staff 
Weaknesses of a 
research project:  
Sl1. The need for high-
tech equipment  
Sl2. The need for high 
precision planning  
Sl3. The involvement of 
a large number of staff  
Sl4. High risk of error 
Sl5. The need for 
additional checks 
Opportunities: 
B1. Infrastructure use in Tomsk Regional 
Oncological Center 
B2. Decrease in treatment time 
B3 Improvement of the effectiveness of 
treatment in general 
B4 Tomsk Regional Oncological Center 
Competitiveness Improvement 
B5 Formation of new recommendations. 
  
Threats: 
U1. Treatment mismatch 
U2. Plan failure 
U3. Equipment breakdown 
U4. Lack of qualifications 
U5. Congestion center 
  
The second stage is to identify the strengths and weaknesses of the research project 
with environmental conditions. This correspondence or inconsistency should help to 
identify the extent to which strategic change is needed. The result of the second stage 
is presented in Table 14. 
Table 14- INTERACTIVE PROJECT MATRIX 
 The strengths of the project 
C1 C2 C3 C4 C5 
 
Possibilities 
Project 
B1 + + + + + 
B2 + + + + + 
B3 + + 0 - - 
B4 + + - + + 
B5 + + 0 + + 
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The third is the final SWOT-analysis matrix Table 15. 
 
Table 15 - SWOT FINAL ANALYSIS MATRIX 
 Strengths of a research 
project: 
C1. Shipping Modern 
treatment 
C2. Use hypofractionation 
C3. High Performance 
Center 
C4. High effectiveness of 
treatment 
C5. High Qualification 
Involved Staff 
Weaknesses of a research 
project:  
Sl1. The need for high-tech 
equipment  
Sl2. The need for high precision 
planning  
Sl3. The involvement of a large 
number of staff  
Sl4. High risk of error 
Sl5. The need for additional 
checks 
Opportunities: 
B1. Infrastructure use in Tomsk 
Regional Oncological Center. 
B2. Decrease in treatment time 
B3 Improvement of the 
effectiveness of treatment in 
general 
B4 Tomsk Regional 
Oncological Center 
Competitiveness Improvement 
B5 Formation of new 
recommendations 
1. The ability to accept 
more patients 
2. The growth of the 
prestige of the center 
1. When planning, it is possible 
to make independent control 
2. Availability of necessary 
equipment in Tomsk Regional 
Oncological Center  
Threats: 
U1. Treatment mismatch 
U2. Plan failure 
U3. Equipment breakdown 
U4. Lack of qualifications 
U5. Congestion center 
1. Ability to improve 
procedures and standards 
1. Timely procedures for 
inspection and verification of 
equipment performance will 
reduce the risk of breakdown 
and the need for repairs 
 
 
This section identifies the key strengths and weaknesses of the project, as well as 
factors affecting the outcome of the work, such as project opportunities and threats. 
A combined analysis of these factors helped to understand how the project should 
be developed and what situations should be avoided in the future. 
 
5.4 Control events of the project 
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Within the framework of this section, the key events of the project are identified, 
their dates and results, which were obtained as of these dates. Information is 
presented in table 16. 
 
Table 16 - PROJECT CONTROL EVENTS 
 
No. Control event Date 
Result 
(confirming document) 
1 Develop a technical task 10.02.2020- 13.02.2020 
Graduation Qualification 
Orders 
2 
Determining the direction of 
the study 
13.02.2020- 15.02.2020 - 
3 Literature analysis and study 14.02.2020- 15.03.2020 
Literary review data-list 
(Literature) 
4 
Exploring hardware and 
software 
10.03.2020- 15.03.2020 - 
5 
Creating, verifying treatment 
plans for SBRT 
15.03.2020- 06.04.2020 - 
6 
Analysis and processing of the 
data obtained 
06.04.2020- 26.04.2020 Report 
7 
Comparison Results 
international requirements 
26.04.2020- 15.05.2020 - 
8 Making an explanatory note 15.05.2020- 30.05.2020 Explanatory Note 
9 
Preparing to defend the 
dissertation work 
31.05.2020- 15.06.2020 Presentation 
 
5.5 Project Plan 
 
 
5.5.1 Hierarchical structure of project work 
 
 
 
             In the process of creating a hierarchical structure of the project structured the 
contents of the entire project, which presented in Figure 31. 
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Figure 31 - Hierarchical structure of works. 
A group of planning processes consists of processes carried out to determine 
the overall content of work, clarify goals and develop a sequence of actions required 
to achieve these goals. Hierarchical structure of work (HSW) - detailing the enlarged 
structure of work. 
As part of the planning of a scientific project, it is necessary to construct a 
project schedule presented in table 17. Next, using the Grant chart in table 18, the 
project schedule is illustrated, on which the work on the topic is characterized by the 
start and end dates of these works. 
 
Table 17 - PROJECT CALENDAR PLAN 
No Name 
Calendar 
time in days 
Date 
Composition 
Participants 
1 
Development of technical 
specifications 
3 10.02.2020 - 13.02.2020 Head 
2 
Determining the direction 
of research 
2 13.02.2020 - 15.02.2020 
Head 
Master 
3 
Analysis and study of 
literature 
30 14.02.2020 - 15.03.2020 Master 
4 
Studying hardware and 
software 
4 10.03.2020 - 15.03.2020 
Head 
Master 
5 
Creation, verification of 
treatment plans for SBRT 
21 15.03.2020 - 05.04.2020 
Head 
Master 
6 
Analysis and processing 
of data 
20 06.04.2020- 26.04.2020 Master 
7 
Comparison of results 
with international 
requirements 
20 26.04.2020- 15.05.2020 Master 
78 
 
8 
Issuing an explanatory 
note 
15 15.05.2020- 30.05.2020 
Head 
Master 
9 
Preparation for the 
defense of the thesis 
16 31.05.2020- 15.06.2020 Master 
 
 
 
 
Table 18 - CALENDAR CHART IN THE FORM OF GRANT 
CHART.    
 
 
  
 -Head 
  
 
- Master 
          
-Head + Master 
 
+                                                                        
 
No
. 
Type of work Performers Calendar 
time in 
days 
Duration of work 
Ф М А М И 
2 3 1 2 3 1 2 3 1 2 3 1 2 
1 Development of technical 
specifications 
Head 3              
2 Determining the direction 
of research 
Head 
Master 
2              
3 Analysis and study of 
literature 
Master 30              
4 Studying hardware and 
software 
Head 
Master 
4              
5 Creation, verification of 
treatment plans for SBRT 
Head 
Master 
21              
6 Analysis and processing 
of data 
Master 20              
7 Comparison of results 
with international 
requirements 
Master 20              
8 Issuing an explanatory 
note 
Head 
Master 
15              
9 Preparation for the 
defense of the thesis 
Master 16              
 
5.6 Budget for scientific and technical research (RST) 
 
 
 
When planning the budget for RST, a full and reliable reflection of all types 
of expenses associated with its implementation should be ensured. In the process of 
budgeting the RST, the following cost grouping is used by items: 
a) materials. 
Table 17 continuation 
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b) the cost of labor of employees directly involved in the final qualification 
work of the master. 
c) contributions to extrabudgetary funds. 
d) work performed by third parties. 
e) special equipment for scientific and experimental work. 
f) other direct costs. 
g) overhead. 
 
5.7 Calculation of material costs  
 
 
 
The main costs in this research work are the costs of electricity when working 
on a planning system, personal computer and a linear accelerator. The cost of 
electricity was also included in the material costs of the STI. Electricity costs are 
calculated by the formula 8: 
Cэлэкт = Цэл * Р * Fоб                                                 (8) 
where Цэл - tariff for industrial electricity (5.8 rubles per 1 kilowatt per hour); 
 P - equipment power is measured in kW; 
Fоб   - the time of use of the equipment in hours. 
When performing the work, a stationary computer with an average power of 
550 W (0.55 kW) was used. All work was performed on it for 4 hours a day all the 
time the work was done 91 days 364 hours.  
Cэлэкт = 5.8 * 0.55* 364 = 1161 rub 
The cost of electricity consumed by the accelerator and related elements are: 
Cэлэкт = 5.8 * 30 * 2 = 348 rub 
The results of calculations for the costs of materials are shown in table 19. 
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Table 19- MATERIALS COST RESULTS. 
Name 
Power of  
equipment 
Quantity, 
hour 
Unit 
price, rub 
Amount, 
rub 
Electricity consumed by 
dosimetric equipment 
(ArcCHECK) 
30 2 5.8 348 
Electricity consumed by 
the accelerator and 
related systems (Elekta 
Synergy linear 
accelerator) 
30 2 5.8 348 
Electricity consumed by 
a personal computer and 
related device 
 
0.55 
 
364 
 
5.8 
 
1161 
Name 
Paper 
SvetoCop
y 
1 
paquete 
280 280 
Printer ink - 
2 
cartridge 
150 300 
Pen Bic 1 200 200 
Internet Tomtel 4 months 450 1800 
Total for materials 2580 
Transportation and procurement costs (3-5%) 0 
Total for Article 7017 
 
 
5.8 calculation of the cost of depreciation for equipment for 
experimental work 
 
 
 
The equipment used in the scientific work was already available in the 
radiology department, so this article describes the costs in the form of 
depreciation. In this thesis, the special equipment necessary for conducting 
experimental work includes: 
a) Elekta Synergy linear accelerator, the cost is 182,000,000 rubles for a 
designated life of 30 years; 
b) a cylindrical dosimetric phantom ArcCHECK, the cost is 6,000,000 rubles for 
a designated life of 15 years. 
The cost of depreciation of equipment is calculated by the formula 9:          
                                                           Соб*На%  
                        Саморт   =    
                                            Тгод*100% 
Т, (9) 
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Where: Соб - the cost of equipment in rubles; 
  На% - the rate of amortization;  
  Тгод - Number of working days per year 
  T - lifespan, in the number of days. 
The depreciation rate is calculated as the reciprocal of the life of the 
equipment, multiplied by 100%. The number of working days in a year is equal to 
2020 - 251.  
The equipment was used with stops for 4 months, but not continuously, for 
the accelerator 76 working days, and for the phantom 25 working days. 
 
 
 
5.9 The cost of labor of performers Scientific Technical Research 
 
 
 
This article includes the basic salary of scientific and engineering workers 
directly involved in the implementation of work on this topic. The amount of 
expenses on wages is determined on the basis of the complexity of the work 
performed and the current system of remuneration. The fee is calculated according 
to the formula 10: 
Сзп = Зос + Здоп,                                                 (10) 
Where Зос is the basic salary; 
Здоп - additional salary  
 
The basic salary of a supervisor is calculated on the basis of industry wages. 
The industry system of remuneration in TPU involves the following composition of 
wages: 
a) Salary - determined by the company. In TPU, salaries are distributed in 
accordance with the positions held, for example, assistant, teacher, assistant 
professor, professor. 
Cаморт = Соб  =  182000000 * 76 + 6000000 * 25 = 1836919+39841=1876760 rub. 
               T        30 * 251             15 * 251 
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b) Incentive payments - are established by the head of departments for effective 
work, the performance of additional duties, etc. Additional wages include payment 
for unworked time (regular and study leave, fulfillment of state duties, payment of 
remuneration for seniority, etc.) and is calculated based on 10-15% of the basic 
wage, employees directly involved in the implementation of the theme are calculated 
by formula 11: 
Здоп = Кдоп * Зосн,                                           (11) 
 
 
where Здоп - additional salary in rubles; 
Кдоп  - additional salary ratio; 
Зосн - basic salary in rubles. 
The main salary of the head is calculated by the formula 12: 
Зосн = Здн * Траб,                                            (12)       
 
Where Зосн - is the basic salary of one employee; 
 Траб - the duration of the work performed by the scientific and technical   
worker in working days; 
 Здн  - the average daily salary of the employee in rubles. 
The average daily wage is calculated by the formula 13: 
                                        Здн =
ЗММ
𝐹д
=  
Зб𝐾𝑝М
𝐹д
                                       (13)  
 
where Зм - the monthly official salary of the employee, rubles; 
M - the number of months of work without vacation during the year; 
when you leave at 24 workday M = 11.2 months, 5-day week, 
when leaving at 48 workday M = 10.4 months, 6-day week; 
 Fд - the actual annual fund of working time of scientific and technical 
personnel (in working days); 
 Зб - base salary; 
 кр - a district coefficient of 1.3 for Tomsk. 
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The base salary of an engineer at the department of NI TPU, having the degree 
of candidate of technical sciences and the title of “teacher” is 35 120 rubles. The 
main salary of the head for the period of work (38 working days) is: 
Здн =
ЗмМ
𝐹д
=
ЗбКрМ
𝐹д
=
35120∗1,3∗10,4
299−48
= 1892 𝑟𝑢𝑏/𝑝𝑒𝑟 𝑑𝑎𝑦  
Зосн = Здн ∗ Траб = 1892 ∗ 38 = 71896 𝑟𝑢𝑏 
Здоп = Кдоп ∗ Зосн = 0,15 ∗ 71896 = 10784,4 𝑟𝑢𝑏 
Сзп = 71896 + 10784,4 = 82680,4 𝑟𝑢𝑏 
Master's salary is 17 310 rubles / month. The work was carried out for four 
months (80 working days), which means the total wage rate is equal to: 
Здн =
ЗмМ
𝐹д
=
ЗбКрМ
𝐹д
=
17310∗1,3∗10,4
247−24
= 1049,4 𝑟𝑢𝑏/𝑝𝑒𝑟 𝑑𝑎𝑦  
Зосн = Здн ∗ Траб = 1049,4 ∗ 80 = 83952 𝑟𝑢𝑏 
Здоп = Кдоп ∗ Зосн = 0,15 ∗ 83952 = 12593 𝑟𝑢𝑏 
Сзп = 83952 + 12593 = 96545 𝑟𝑢𝑏 
5.9.1 Contributions to extrabudgetary funds 
 
 
 
The amount of contributions to extrabudgetary funds is 27.1% in 2020 of the 
total cost of labor of employees directly involved in the performance of work. 
                                    Свнеб = Квнеб ∗ (Зос + Здоп)                                               (14)                                                                    
              Where Квнеб is the coefficient of contributions to social funds. 
                   Свнеб = 0,271 ∗ (74098,3 + 𝑟𝑢𝑏, 4) = 22819 rub 
 
5.9.2 General expenses  
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To take into account the general costs, it is necessary to take into account the 
costs of maintaining the management apparatus and the general economic services 
(university), which apply equally to all scientific research work carried out. This 
article takes into account the remuneration of administrative staff, the maintenance 
of buildings, office equipment and household goods, depreciation of property, labor 
protection and training costs. 
General expenses take into account other expenses of the organization that are 
not included in the items of previous expenses: printing and photocopying of 
research materials, payment for communication services, electricity, postal and 
telegraphic costs, reproduction of materials, etc. Its value is determined by the 
following formula: 
Знакл = Кнр ∗ (сумма статей 1 ÷ 6)                           (15) 
where Кнр is the coefficient taking into account overhead costs. 
The value of the overhead coefficient is taken in the amount of 15%. 
           Знакл = 0,15 ∗ (74098,3 ÷ 10104,4) = 12630,4  rub 
5.9.3 Formation of the budget for the costs of scientific and technical 
research (STR) 
 
 
 
          The calculated value of the research work is the basis for the formation of the 
project cost budget. The definition of the budget for the research project for each 
implementation option is given in table 20. 
Table 20 - CALCULATION OF THE BUDGET EXPENDITURES STR 
Title of the article Cost of expenses in rubles 
1. Material costs of STR 7017 
2. The cost of equipment 1907153 
3. Main staff costs involved in the interpretation of the subject 179225.4 
4. Extra Budgetary contributions (funds) 22819 
5. General expenses 12630,4 
Total cost of budget STR 2128844.8 
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The planned cost of work is 2128844.8 rub.  
 
          5.9.4 Organizational structure of the project 
 
 
 
The structure most appropriate to this work is the project structure, which 
includes all its participants and is created to successfully achieve the goals of the 
project. The organizational structure of this project is shown in Figure 32. 
 
 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 32- The organizational structure of the project 
 
         5.9.5 Responsibility Matrix 
 
 
 
The liability matrix determines the degree of responsibility of each member 
of the project for a task, if he has something to do with it. 
 
 
 
Nuclear  
Engineering 
School 
Scientific  
adviser 
Consultant in 
English 
Social 
Responsibility 
Consultant 
Consultant in the section 
Financial Management, Resource 
Efficiency and Resource Saving 
Executor 
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Table 21- RESPONSIBILITY MATRIX 
 
Project stages 
Scientific 
adviser 
Consultant 
English 
language 
Consultant 
management 
Consultant 
Social 
Respons. 
Master 
Analysis and 
study of literature 
О    И 
Hardware and 
software study 
О    И 
Creation, 
verification of 
treatment plans for 
SBRT 
О    И 
Analysis and 
processing of data 
О    И 
Comparison of 
results with 
international 
requirements 
О    И 
Issuing an 
explanatory note 
С    И 
Preparation for the 
defense of the 
thesis 
С    И 
Resource 
Efficiency and 
Resource 
Evaluation 
  С  И 
Social 
Responsibility 
Section 
   С И 
English translation  С   И 
Responsible (O) - the person responsible for the implementation of the project phase and 
monitoring its progress. Contractor (I) - the person (s) performing work as part of the project phase. 
Approver (U) - the person who approves the results of the project stage (if the stage provides for 
approval). Coordinator (C) - a person who analyzes the results of the project and participates in 
the decision on whether the results of the stage meet the requirements. 
 
5.9.6 Calculation of scientific and technical effect 
 
 
 
Recently, to assess the scientific value, technical significance and 
effectiveness of planned and performed work, the method of point estimates has 
been widely used, on the basis of which it is concluded that R&D is appropriate. The 
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essence of this technique is that based on the assessment of the signs of work, the 
coefficient of the scientific and technical effect of R&D is determined by the formula 
16: 
Н = ∑ К𝐼
3
𝑖=1 ∗ 𝑛𝑖                                                      (16) 
where Н is an indicator of the Scientific and Technical Level (STL); 
k is the weight coefficient of the i-th attribute of STL; 
n is the score (in points) of the i-th attribute. 
Table 22 shows the assessment of STL Graduation work (WRC). 
 
Table 22- ASSESSMENT OF STL GRADUATION WORK (WRC). 
Sign of STL weight coefficient Characteristic 
development 
Selected 
point 
Novelty level 0.6 New 8 
Theoretical Results 0.4 Statement of experience 1 
Possibility of implementation 0.2 During the first years 10 
industry 4 
Н = 8 ∗ 0,6 + 1 ∗ 0,4 + 10 ∗ 0,2 + 4 ∗ 0,2 = 8 
 
According to the STL scale, this scientific and technical work corresponds to 
a relatively high level. 
 
5.10 Reference of financial management, resource efficiency and resource 
saving 
 
 
 
1. Financial management, resource efficiency and resource conservation: a 
training manual / I.G. Vidyaev, G.N. Serikova, N.A. Gavrikova, N.V. Shapovalova, 
L.R. Tukhvatulina Z.V. Krinitsyna; Tomsk Polytechnic University. - Tomsk: 
Publishing house of Tomsk Polytechnic University, 2014. - 36 p. 
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6 SOCIAL RESPONSIBILITY 
 
 
       6.1 Introduction 
 
 
 
      The objective of the work was to prepare and describe the VMAT plans, to 
carry out evaluation qualitative for the critical organs and evaluation qualitative of 
the quality control plans for five patients with liver metastases. 
      The process of research was carried out on at the Tomsk Regional Oncology 
Center. Application area: Radiotherapy, oncology. 
      For 5 patients with metastases liver, RT planning, an independent verification 
of radiation plans, and treatment delivery using fractionated SBRT with a VMAT 
dose delivery technique were performed. To conduct topometric preparation for all 
patients, Elekta Synergy is a high-energy linear accelerator with an intensity 
modulation function was used. The complex of means for immobilizing patients 
during topometric preparation and the treatment itself consisted of a system ABC. 
To create an exposure plan, a dosimetric planning system was used with a dose 
calculation algorithm based on the Monte Carlo Monaco method (version 5.1).  
     An analysis of the results of therapy obtained during work for the five patients 
suggests a favorable outcome of treatment of liver metastasis with SBRT. 
     To achieve our objective, we carried out the measures related to the evaluation 
of patients with liver metastases and the application of the established protocol for 
the management of this disease, in order to improve the patient's quality of life. 
 
6.2 Legal and organizational items in providing safety 
 
 
 
            Occupational safety is a system of legislative, socio-economic, 
organizational, technological, hygienic and therapeutic and prophylactic measures 
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and tools that ensure the safety, preservation of health and human performance in 
the work process [1]. 
According to the Labor Code of the Russian Federation, every employee has 
the right: 
a) to have a workplace that meets Occupational safety requirements; 
b) to have a compulsory social insurance against accidents at manufacturing 
and occupational diseases; 
c) to receive reliable information from the employer, relevant government 
bodies and public organizations on conditions and Occupational safety at the 
workplace, about the existing risk of damage to health, as well as measures to protect 
against harmful and (or) hazardous factors; 
d) to refuse carrying out work in case of danger to his life and health due to 
violation of Occupational safety requirements; 
e) be provided with personal and collective protective equipment in 
compliance with Occupational safety requirements at the expense of the employer; 
f) for training in safe work methods and techniques at the expense of the 
employer; 
g) for personal participation or participation through their representatives in 
consideration of issues related to ensuring safe working conditions in his workplace, 
and in the investigation of the accident with him at work or occupational disease; 
h) for extraordinary medical examination in accordance with medical 
recommendations with preservation of his place of work (position) and secondary 
earnings during the passage of the specified medical examination; 
i) for warranties and compensation established in accordance with this Code, 
collective agreement, agreement, local regulatory an act, an employment contract, if 
he is engaged in work with harmful and (or) hazardous working conditions. 
 
6.3  Basic ergonomic requirements for the correct location and 
arrangement of researcher’s workplace  
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The workplace when working with a PC should be at least 6 square meters. 
The legroom should correspond to the following parameters: the legroom height is 
at least 600 mm, the seat distance to the lower edge of the working surface is at least 
150 mm, and the seat height is 420 mm. It is worth noting that the height of the table 
should depend on the growth of the operator. 
The following requirements are also provided for the organization of the 
workplace of the PC user: The design of the working chair should ensure the 
maintenance of a rational working posture while working on the PC and allow the 
posture to be changed in order to reduce the static tension of the neck and shoulder 
muscles and back to prevent the development of fatigue. 
The type of working chair should be selected taking into account the growth 
of the user, the nature and duration of work with the PC. The working chair should 
be lifting and swivel, adjustable in height and angle of inclination of the seat and 
back, as well as the distance of the back from the front edge of the seat, while the 
adjustment of each parameter should be independent, easy to carry out and have a 
secure fit. 
 
6.4 Occupational safety  
 
 
 
6.4.1 Analysis of harmful and dangerous factors that can create object 
of investigation  
The object of investigation is “to prepare and describe the VMAT plans, to 
carry out evaluation qualitative for the critical organs and evaluation qualitative of 
the quality control plans for five patients with liver metastases”. Therefore, object 
of investigation itself cannot cause harmful and dangerous factors. 
6.4.2. Analysis of harmful and dangerous factors that can arise at 
workplace during investigation  
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            The main elements of the production process that form dangerous and 
harmful factors are presented in Table 23. 
Table 23 - POSSIBLE HAZARDOUS AND HARMFUL FACTORS 
Factors 
(GOST 12.0.003-
2015) 
Work stages 
Legal 
documents Develop
-ment 
Manu-
facture 
Exploi-
tation 
1. Deviation of 
micro-climate 
indicators 
+ + + 
Sanitary rules 2.2.2 / 
2.4.1340–03. Sanitary and 
epidemiological rules and regulations 
"Hygienic requirements for personal 
electronic computers and work 
organization." 
Sanitary rules 2.2.1 / 
2.1.1.1278–03. Hygienic requirements 
for natural, artificial and combined 
lighting of residential and public 
buildings. 
Sanitary rules 2.2.4 / 
2.1.8.562–96. Noise at workplaces, in 
premises of residential, public 
buildings and in the construction area. 
Sanitary rules 2.2.4.548–96. 
Hygienic requirements for the 
microclimate of industrial premises. 
2. Excessive noise  + + 
3.Increased level 
of 
electromagnetic 
radiation 
+ + + 
4. Insufficient 
illumination of the 
working area 
 + + 
5. Abnormally 
high voltage value 
in the circuit, the 
closure which 
may occur 
through the 
human body 
+ + + 
Sanitary rules GOST 12.1.038-82 
SSBT. Electrical safety. Maximum 
permissible levels of touch voltages 
and currents. 
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6. Increased levels 
of ionizing 
radiation 
+ + + 
Sanitary Rules 2.6.1. 2523 -0 9. 
Radiation Safety Standards (NRB-
99/2009). 
        The following factors effect on person working on a computer: 
a) Physical:  
1) temperature and humidity;  
2) noise;  
3) static electricity;  
4) electromagnetic field of low purity; 
5) illumination; 
6) presence of radiation; 
b) Psychophysiological: 
1) Psychophysiological dangerous and harmful factors are divided into:  
- physical overload (static, dynamic)  
- mental stress (mental overstrain, monotony of work, emotional 
overload). 
Deviation of microclimate indicators 
The optimum and permissible values of the microclimate characteristics are 
established in accordance with [2] and are given in Table 24. 
Table 24 - OPTIMAL AND PERMISSIBLE PARAMETERS OF THE 
MICROCLIMATE 
Period of the year Temperature, C 
Relative 
humidity,% 
Speed of air 
movement, m/s 
Cold and changing 
of seasons 
23-25 40-60 0.1 
Warm 23-25 40 0.1 
 Table 23 continuation 
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Increased level of electromagnetic radiation 
The screen and system blocks produce electromagnetic radiation. Its main 
part comes from the system unit and the video cable. According to [2], the intensity 
of the electromagnetic field at a distance of 50 cm around the screen along the 
electrical component should be no more than: 
a) in the frequency range 5 Hz - 2 kHz - 25 V / m; 
b) in the frequency range 2 kHz - 400 kHz - 2.5 V / m. 
The magnetic flux density should be no more than: 
a) in the frequency range 5 Hz - 2 kHz - 250 nT; 
b) in the frequency range 2 kHz - 400 kHz - 25 nT. 
Abnormally high voltage value in the circuit 
Depending on the conditions in the room, the risk of electric shock to a 
person increases or decreases. Do not operate the electronic device in conditions of 
high humidity (relative air humidity exceeds 75% for a long time), high temperature 
(more than 35 ° C), the presence of conductive dust, conductive floors and the 
possibility of simultaneous contact with metal components connected to the ground 
and the metal casing of electrical equipment. The operator works with electrical 
devices: a computer (display, system unit, etc.) and peripheral devices. There is a 
risk of electric shock in the following cases: 
- with direct contact with current-carrying parts during computer repair; 
- when touched by non-live parts that are under voltage (in case of violation of 
insulation of current-carrying parts of the computer); 
- when touched with the floor, walls that are under voltage; 
- short-circuited in high-voltage units: power supply and display unit. 
Table 25 -UPPER LIMITS FOR VALUES OF CONTACT CURRENT AND 
VOLTAGE 
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 Voltage, V Current, mA 
Alternate,  50 Hz 2 0.3 
Alternate,  400 Hz 3 0.4 
Direct 8 1.0 
Insufficient illumination of the working area 
Light sources can be both natural and artificial. The natural source of the light 
in the room is the sun, artificial light are lamps. With long work in low illumination 
conditions and in violation of other parameters of the illumination, visual perception 
decreases, myopia, eye disease develops, and headaches appear. 
According to the standard, the illumination on the table surface in the area of 
the working document should be 300-500 lux. Lighting should not create glare on 
the surface of the monitor. Illumination of the monitor surface should not be more 
than 300 lux. The brightness of the lamps of common light in the area with radiation 
angles from 50 to 90° should be no more than 200 cd/m, the protective angle of the 
lamps should be at least 40°. The safety factor for lamps of common light should be 
assumed to be 1.4. The ripple coefficient should not exceed 5%. 
Increased levels of ionizing radiation 
Ionizing radiation is radiation that could ionize molecules and atoms. This 
effect is widely used in energetics and industry. However, there is health hazard. In 
living tissue, this radiation could damage cells that result in two types of effects. 
Deterministic effects (harmful tissue reactions) due to exposure with high doses and 
stochastic effects due to DNA destruction and mutations (for example, induction of 
cancer). 
To provide radiation safety with using sources of ionizing radiation one must 
use next principles: 
a) keep individual radiation doses from all radiation sources not higher 
than permissible exposure; 
b) forbid all activity with using radiation sources if profit is low than risk 
of possible hazard; 
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c) keep individual radiation doses from all radiation sources as low as 
possible. 
There are two groups of people related to work with radiation: personnel, who 
works with ionizing radiation, and population. 
Table 26 – RADIATION INDEX 
Quantity Dose limits 
personnel population 
Effective dose 20 mSv per year in average 
during 5 years, but not 
higher than 50 mSv per year 
1 mSv per year in average 
during 5 years, but not 
higher than 5 mSv per year 
Equivalent dose per 
year in eye’s lens 
150 mSv 15 mSv 
Skin 500 mSv 50 mSv 
Hands and feet 500 mSv 50 mSv 
 
Effective dose for personnel must not exceed 1000 mSv for 50 years of 
working activity, and for population must not exceed 70 mSv for 70 years of life. 
In addition, for women from personnel of age below 45 years there is limit of 
1 mSv per month of equivalent dose on lower abdomen. During gestation and breast-
feeding women must not work with radiation sources. 
For students older than 16, who uses radiation sources in study process or who 
is in rooms with increased level of ionizing radiation, dose limits are quarter part of 
dose limits of personnel. 
6.4.3 Justification of measures to reduce the levels of exposure to 
hazardous and harmful factors on the researcher 
 
 
 
Deviation of microclimate indicators 
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The measures for improving the air environment in the production room 
include: the correct organization of ventilation and air conditioning, heating of room. 
Ventilation can be realized naturally and mechanically. In the room, the following 
volumes of outside air must be delivered:  
a) at least 30 m 3 per hour per person for the volume of the room up to 20 m 3 per 
person;  
b) natural ventilation is allowed for the volume of the room more than 40 m 3 per 
person and if there is no emission of harmful substances. 
The heating system must provide sufficient, constant and uniform heating of 
the air. Water heating should be used in rooms with increased requirements for clean 
air.  
The parameters of the microclimate in the laboratory regulated by the central 
heating system, have the following values: humidity 40%, air speed 0.1 m / s, 
summer temperature 20-25 ° C, in winter 13-15 ° C. Natural ventilation is provided 
in the laboratory. Air enters and leaves through the cracks, windows, doors. The 
main disadvantage of such ventilation is that the fresh air enters the room without 
preliminary cleaning and heating. 
Excessive noise 
In research audiences, there are various kinds of noises that are generated by 
both internal and external noise sources. The internal sources of noise are working 
equipment, personal computer, printer, ventilation system, as well as computer 
equipment of other engineers in the audience. If the maximum permissible 
conditions are exceeded, it is sufficient to use sound-absorbing materials in the room 
(sound-absorbing wall and ceiling cladding, window curtains). To reduce the noise 
penetrating outside the premises, install seals around the perimeter of the doors and 
windows. 
Increased level of electromagnetic radiation 
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There are the following ways to protect against EMF: 
a) increase the distance from the source (the screen should be at least 50 cm from 
the user); 
b) the use of pre-screen filters, special screens and other personal protective 
equipment. 
When working with a computer, the ionizing radiation source is a display. 
Under the influence of ionizing radiation in the body, there may be a violation of 
normal blood coagulability, an increase in the fragility of blood vessels, a decrease 
in immunity, etc. The dose of irradiation at a distance of 20 cm to the display is 50 
µrem / hr. According to the norms [2], the design of the computer should provide 
the power of the exposure dose of x-rays at any point at a distance of 0.05 m from 
the screen no more than 100 µR / h. 
Increased levels of ionizing radiation 
Radiation control is a main part of radiation safety and radiation protection.  
It is aimed at not exceeding the established basic dose limits and permissible levels 
of radiation, obtaining the necessary information to optimize protection and making 
decisions about interference in the case of radiation accidents, contamination of the 
environment and buildings with radionuclides. 
The radiation control is control of: 
a) radiation characteristics of radiation sources, pollution in air, liquid and solid 
wastes. 
b) radiation factors developed with technological processes in working places and 
environment. 
c) radiation factors of contaminated environment. 
d) irradiation dose levels of personnel and population. 
The main controlled parameters are: 
a) annual effective and equivalent doses 
b) intake and body content of radionuclides 
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c) volume or specific activity of radionuclides in air, water, food products, building 
materials and etc. 
d) radioactive contamination of skin, clothes, footwear, working places and etc. 
e) dose and power of external irradiation. 
f) particles and photons flux density. 
Radiation protection office establish control levels of all controlled parameters 
in according to not exceed dose limits and keep dose levels as low as possible. In 
case of exceeding control levels radiation protection officers start investigation of 
exceed causes and take actions to eliminate this exceeding. 
Insufficient illumination of the working area 
Desktops should be placed in such a way that the monitors are oriented 
sideways to the light openings, so that natural light falls mainly on the left. 
Also, as a means of protection to minimize the impact of the factor, local 
lighting should be installed due to insufficient lighting, window openings should be 
equipped with adjustable devices such as blinds, curtains, external visors, etc. 
 
          6.5 Ecological safety  
 
 
6.5.1 Analysis of the impact of the research object on the environment 
 
 
 
Sources of ionizing radiation used in medicine could be divided into two 
groups: radioactive substances and radiation generators. The difference is that 
radiation generators like accelerators and x-ray tubes emit ionizing radiation only 
when they are turned on.   
In ordinary work with necessary safety precautions, there are insignificant 
impact of using sources of ionizing radiation on environment. The immediate effect 
of ionizing radiation is ionization of air in room, but after a specified time the 
ionization disappears. 
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The danger of using radioactive materials could occur only in accidents with 
stealing and loosing these materials due to high toxicity. 
 
6.5.2 Analysis of the environmental impact of the research process 
 
 
 
Process of investigation itself in the thesis do not have essential effect on 
environment. One of hazardous waste is fluorescent lamps. Mercury in fluorescent 
lamps is a hazardous substance and its improper disposal greatly poisons the 
environment. 
Outdated devices goes to an enterprise that has the right to process wastes. It 
is possible to isolate precious metals with a purity in the range of 99.95–99.99% 
from computer components. A closed production cycle consists of the following 
stages: primary sorting of equipment; the allocation of precious, ferrous and non-
ferrous metals and other materials; melting; refining and processing of metals. Thus, 
there is an effective disposal of computer devices. 
 
6.5.3 Justification of environmental protection measures 
 
 
 
 Pollution reduction is possible due to the improvement of devices that 
produces electricity, the use of more economical and efficient technologies, the use 
of new methods for generating electricity and the introduction of modern methods 
and methods for cleaning and neutralizing industrial waste. In addition, this problem 
should be solved by efficient and economical use of electricity by consumers 
themselves. This is the use of more economical devices, as well as efficient regimes 
of these devices. This also includes compliance with production discipline in the 
framework of the proper use of electricity. 
            Simple conclusion is that it is necessary to strive to reduce energy 
consumption, to develop and implement systems with low energy consumption. In 
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modern computers, modes with reduced power consumption during long-term idle 
are widely used. 
 
           6.6 Safety in emergency 
 
 
 
 6.6.1 Analysis of probable emergencies that may occur at the workplace during 
research 
 
 
 
            The fire is the most probable emergency in our life. Possible causes of fire: 
a) malfunction of current-carrying parts of installations; 
b) work with open electrical equipment; 
c) short circuits in the power supply; 
d) non-compliance with fire safety regulations; 
e) presence of combustible components: documents, doors, tables, cable insulation, 
etc. 
Activities on fire prevention are divided into: organizational, technical, 
operational and regime. 
 
6.6.2 Substantiation of measures for the prevention of emergencies and 
the development of procedures in case of emergencies 
 
 
 
Organizational measures provide for correct operation of equipment, proper 
maintenance of buildings and territories, fire instruction for workers and employees, 
training of production personnel for fire safety rules, issuing instructions, posters, 
and the existence of an evacuation plan. 
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The technical measures include compliance with fire regulations, norms for 
the design of buildings, the installation of electrical wires and equipment, heating, 
ventilation, lighting, the correct placement of equipment. 
The regime measures include the establishment of rules for the organization 
of work, and compliance with fire-fighting measures. To prevent fire from short 
circuits, overloads, etc., the following fire safety rules must be observed: 
a) elimination of the formation of a flammable environment (sealing equipment, 
control of the air, working and emergency ventilation); 
b) use in the construction and decoration of buildings of non-combustible or 
difficultly combustible materials; 
c) the correct operation of the equipment (proper inclusion of equipment in the 
electrical supply network, monitoring of heating equipment); 
d) correct maintenance of buildings and territories (exclusion of the source of 
ignition - prevention of spontaneous combustion of substances, restriction of fire 
works); 
e) training of production personnel in fire safety rules; 
f) the publication of instructions, posters, the existence of an evacuation plan; 
g) compliance with fire regulations, norms in the design of buildings, in the 
organization of electrical wires and equipment, heating, ventilation, lighting; 
h) the correct placement of equipment; 
i) well-time preventive inspection, repair and testing of equipment. 
In the case of an emergency, it is necessary to: 
a) inform the management (duty officer); 
b) call the Emergency Service or the Ministry of Emergency Situations - tel. 112; 
c) take measures to eliminate the accident in accordance with the instructions. 
 
           6.7 Conclusions of social responsibility  
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In this section about social responsibility the hazardous and harmful factors 
were revealed. All necessary safety measures and precaution to minimize probability 
of accidents and traumas during investigation are given.  
Possible negative effect on environment were given in compact form 
describing main ecological problem of using nuclear energy.  
It could be stated that with respect to all regulations and standards, 
investigation itself and object of investigation do not pose special risks to personnel, 
other equipment and environment. 
            6.8 References of social responsibility 
 
 
 
 
1 Federal Law "On the Fundamentals of Labor Protection in the Russian 
Federation" of 17.07.99 № 181 – FZ. 
2 SanPiN 2.2.2 / 2.4.1340-03. Sanitary-epidemiological rules and standards 
"Hygienic requirements for PC and work organization". 
3 GOST 12.1.038-82 Occupational safety standards system. Electrical safety. 
4 Fire and explosion safety of industrial facilities. GOST R12.1.004-85 
Occupational safety standards system. Fire safety. 
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CONCLUSION 
 
 
 
Five patients with liver metastases were treated at the Tomsk Regional 
Oncology Center, thanks to the range of equipment for remote radiotherapy with 
support for VMAT dose delivery technology, which includes the Elekta Synergy 
linear accelerator and the Monaco  dosimetric planning system, the SBRT 
procedure was possible for the treatment of liver metastases. Based on the dose-
volume histogram (DVH), the plans were evaluated, the most optimal treatment 
plan was selected taking into account the tolerant levels of radiation of critical 
organs and the tumor. Using the ArcCHECK cylindrical dosimetric phantom 
supported by 3DVH software, verification of the treatment plan was produced 
undistorted and provided an analysis of the reasons for mismatch / plan mismatch 
according to the necessary selection criteria. The ABC or Active breathing 
coordinator system is the respiratory gating system used with the Elekta treatment 
machine. Importance is highlighted of respiratory management during 
radiotherapy treatment to ensure optimal dose delivery to both the tumor volume 
and surrounding organs. Although breathing evaluation was not described in this 
study, an analysis is recommended of the measured dose distributions to 
determine if the level of coverage is similar in dependence on the breathing rates 
from other studies.  
Analysis of treatments data and results of MRI exams concludes that liver 
metastases were more common in the right lobe than in the left lobe in this study. 
Finally, it is concluded that SBRT technique gets much advantages in 
clinical practice, ensuring delivering prescribed dose to the target and minimizing 
dose to the surrounding normal tissues, so it requires high accuracy and 
synchronous facilities. Although it takes much time for planning, the duration of 
treatment is short. This is an accurate and safe technique in modern radiation 
therapy. 
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FUTURE WORK 
 
 
 
While this project has established that VMAT is a viable treatment option for liver 
metastases, no testing procedures were performed using respiratory management 
to determine which method provides optimal dose restrictions. In the plans created 
for the five patients of this investigation, the VMAT plan developed adequate dose 
coverage without higher doses for organs at risk. A planning study should be 
undertaken by experienced planning staff to determine which technique offers the 
best dosimetric outcomes. These outcomes should also be weighed against other 
factors including reduced treatment delivery time for VMAT, planning and 
calculation times, VMAT patient verification measurements and inability to use 
the 6D positioning system with current 4D techniques. 
A novel investigation to follow this project is to repeat the investigation with a 
flattening filter-free (FFF) treatment method. FFF is currently being 
commissioned for use in the Prince of Wales Radiation Oncology department. An 
investigation into the viability of FFF treatment would be required to assess the 
effect of the forward peaked beam and significantly faster dose delivery times 
(approximately 4 times faster for 10 MV Elekta beams). 
Finally, measurements should be repeated for each of the treatment techniques 
following implementation of gating within the department. 
 
 
 
 
 
 
 
 
105 
 
LIST OF STUDENT PUBLICATIONS IN RUSSIAN FEDERATION 
 
 
 
1. HYPERTROPHIC CARDIOMYOPATHY AND RISK FACTORS FOR 
SUDDEN DEATH// International Slavic Congress on Cardiac Electrophysiology 
“KARDIOSTIM”, "Official Journal of the All-Russian Scientific Society of 
Specialists in Clinical Electrophysiology of arithmology and cardiodiagnosis”, 
Russia, St. Petersburg, 2017. 
2. WHAT IS NUCLEAR MEDICINE? // XII Materials of the international 
scientific-practical conference, "Modern Intellectual Transformation of Socio-
Economic Systems, Russia, Saratov, February 15, 2018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
LIST OF REFERENCES 
 
 
 
1. American College of Radiology. ACR-ASTRO practice parameter for the 
performance of stereotactic body radiation therapy, 2014. Available at: 
https://www.acr.org/-/media/ACR/Files/Practice-Parameters/SBRT-RO. 
2. American College of Radiology Practice Guideline for the Performance of 
Stereotactic Body Radiation Therapy. Reston, VA: American College of Radiology; 
2009:8. 
3. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic 
Radiology and Oncology (ASTRO) and American College of Radiology (ACR) 
practice guideline for the performance of stereotactic body radiotherapy. Int J Radiat 
Oncol Biol Phys. 2010;76:326-332. doi:10.1016/j.ijrobp.2009.09.042. 
4. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: 
the report of AAPM Task Group 101. Med Phys. 2010; 37 (8):4078-4101. 
doi:10.1118/1.3438081. 
5. Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of 
Radiation Oncology scope of practice guidelines for lung, liver and spine 
stereotactic body radiotherapy. Clin Oncol. 2012;24(9):629-639. doi: 
10.1016/j.clon.2012.04.006. 
6. Marianne Camille Aznar, Samantha Warren, Mischa Hoogeman, Mirjana 
Josipovic. The impact of technology on the changing practice of lung SBRT. 
https://doi.org/10.1016/j.ejmp.2017.12.020. 
7. Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-
stage colorectal cancer management: the surgeon meets the oncologist. World J 
Gastroenterol. 2014 Jun 28;20(24):7602–21. 
8. Null K, Null R. Liver Metastases. Curr Treat Options Gastroenterol. 
1999;2(1):49–57. 
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 
2017;67(1):7–30. 
107 
 
10. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. 
Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 
necropsies. J Pathol. 1986;150(3):195–203. 
11. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol Off J Am Soc 
Clin Oncol. 1995;13(1):8–10. 
12. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. 
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for 
resectable liver metastases from colorectal cancer (EORTC 40983): long-term 
results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–
15. 
13. Smith JJ, ‘Angelica D MI. Surgical management of hepatic metastases of 
colorectal cancer. Hematol Oncol Clin North Am 201529(1):61–84. 
14. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et 
al. Actual 10-year survival after resection of colorectal liver metastases defines cure. 
J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(29):4575–80. 
15. Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review 
of the safety and efficacy of combination chemotherapies used in the treatment of 
metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014;91(1):9–34. 
16. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue 
surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a 
model to predict long-term survival. Ann Surg. 2004;240(4):644–58. 
17. Hellman S, Weichselbaum RR. Importance of local control in an era of systemic 
therapy. Nat Clin Pract Oncol. 2005;2(2):60–1. 
18. Dawson L.A., Normolle D., Balter J.M., McGinn C.J., Lawrence T.S., Ten 
Haken R.K. Analysis of radiation induced liver disease using the Lyman NTCP 
model. Int J Radiat Oncol Biol Phys. 2002;53:810–821. 
19. Schefter T., Kavanag B., Timmerman R., Cardenes H.R., Baron A., Gaspar L.E. 
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. 
Int J Radiat Oncol Biol Phys. 2005;62:1371–1378. 
108 
 
20. Potters L., Steinberg M., Rose C. American Society of Therapeutic Radiology 
and Oncology and American College of Radiology practice guidelines for the 
performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 
2004;60:1026–1032. 
21. Benedict S., Yenice K., Followill D. Stereotactic body radiation therapy: the 
report of AAPM Task Group 101. Med Phys. 2010;37:4078–4101. 
22. Comito T, Clerici E, Tozzi A, D'Agostino G. Liver metastases and SBRT: A new 
paradigm? Rep Pract Oncol Radiother. 2015;20(6):464–471. 
23. Ricardi U, Badellino S, Filippi AR. Clinical applications of stereotactic radiation 
therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat 
Res. 2016;57(Suppl 1):i58–i68. 
24. Wild AT, Yamada Y. Treatment Options in Oligometastatic Disease: 
Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer. Visc Med. 
2017;33(1):54–61. 
25. Wurm R., Gum F., Erbel L. Image guided respiratory gated hypofractionated 
Stererotactic Body Radiation Therapy (H-SBRT) for liver and lung tumors: initial 
experience. Acta Oncol. 2006;45:881–889. 
26. Verellen D., Soete G., Linthout N. Quality assurance of a system for improved 
target localization and patient set-up that combines real-time infrared tracking and 
stereoscopic X-ray imaging. Radiother Oncol. 2003;67:129–134. 
27. Herfarth K., Debus J., Lohr F. Stereotactic single-dose radiation therapy of liver 
tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164–170. 
28. Katz A.W., Carey-Sampson M., Muhs A.G. Hypofractionated stereotactic body 
radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol 
Phys. 2007;67:793–798. 
29. Rusthoven K.E., Kavanagh B.D., Cardenes H. Multi-institutional phase I/II trial 
of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 
2009;27:1572–1578. 
30. Chang D.T., Swaminath A., Kozak M. Stereotactic body radiotherapy for 
colorectal liver metastases: a pooled analysis. Cancer. 2011;117:4060–4069. 
109 
 
31. Scorsetti M., Arcangeli S., Tozzi A. Is stereotactic body radiation therapy an 
attractive option for unresectable liver metastases? A preliminary report from a 
phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86:336–342. 
32. Berber B., Ibarra R., Snyder L. Multicentre results of stereotactic body 
radiotherapy for secondary liver tumours. HPB (Oxford) 2013;15:851–857. 
33. Hernando O., Sánchez E., Fernández-Letón P. Institutional experience on the 
treatment of lung and liver lesions with stereotactic body radiotherapy with Novalis 
Exactrac Adaptive Gating Technique. J Radiosurg SBRT. 2011;3:231–236. 
34. Andratschke N., Nieder C., Heppt F., Molls M., Zimmermann F. Stererotactic 
radiation therapy for liver metastases: factors affecting local control and survival. 
Radiat Oncol. 2015;10:69. 
35. Comito T., Clerici E., Tozzi A., D’Agostino G. Liver metastases and SBRT. A 
new paradigm? Rep Pract Oncol Radiother. 2015;20:464–471. 
36. Rubio C., Morera R., Larigau E., Hernando O., Leroy T. Extracranial stereotactic 
body radiotherapy. Review of main. A new paradigm? Rep Pract Oncol Radiother. 
2013;18(6):387–396. 
37. Scorsetti M. Stereotactic body radiotherapy: A useful weapon in anticancer 
treatment. Rep Pract Oncol Radiother. 2015;20(6). 
38. Carmen Rubio,a, Ovidio Hernando-Requejo,a Daniel Zucca Aparicio, María A. 
Llona Krauel, Mercedes López Gonzalez. Image guided SBRT for multiple liver 
metastases with ExacTrac® Adaptive Gating. Rep Pract Oncol Radiother. 2017 
Mar-Apr; 22(2): 150–157. Published online 2016 Sep 17. doi: 
10.1016/j.rpor.2016.07.006. 
39. McCammon R., Schefter T.E., Gaspar L.E., Zaemisch R., Gravdahl D., 
Kavanagh B. Observation of a dose-control relationship for lung and liver tumors 
after stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 
2009;73(1):112–118. 
40. Jones, Bryan & Dale, Roger & Deehan, C & Hopkins, K & Morgan, David. 
(2001). The Role of Biologically Effective Dose (BED) in Clinical Oncology. 
110 
 
Clinical oncology (Royal College of Radiologists (Great Britain)). 13. 71-81. 
10.1053/clon.2001.9221. 
41. Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. 
Semin. Radiat. Oncol 2011;21(4):256–63. 
42. De Bari B, Guillet M, Mornex F. Radiothérapie en conditions stéréotaxiques des 
métastases hépatiques. Cancer/Radiothérapie 2011;15(1):72–6. 
43. Pan CC, Kavanagh BD, Dawson La, et al. Radiation-associated liver injury. Int. 
J. Radiat. Oncol. Biol. Phys 2010;76(3, Suppl.):94–100. 
44. Thomas TO, Hasan S, Small W, et al. The tolerance of gastrointestinal organs to 
stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol 
2014;5(3):236–46. 
45. Murphy JD, Hattangadi-Gluth J, Song WY, et al. Liver toxicity prediction with 
stereotactic body radiation therapy: the impact of accounting for fraction size. Pract 
Radiat Oncol 2014;4(6):372–7.  
46. Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver 
metastases: update of the initial phase-I/II trial. Front. Radiat. Ther. Oncol 
2004;38:100–5. 
47. Mendez Romero A, Bakri L, Seppenwoolde Y, et al. Inter- and intraobserver 
variability in daily tumor setup using contrast-enhanced CT scans for patient 
positioning during stereotactic body radiation therapy for liver metastases. Int J 
Radiat Oncol 2013;87(2, Suppl.):S318. 
48. De Bari B, Pointreau Y, Rio E, Mirabel X, Mornex F. Dose de tolérance à 
l’irradiation des tissus sains: le foie. Cancer/Radiothérapie 2010;14(4–5):344–9. 
49. Sanuki N, Takeda A, Oku Y, et al. Threshold doses for focal liver reaction after 
stereotactic ablative body radiation therapy for small hepatocellular carcinoma 
depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-
DTPA. Int. J. Radiat. Oncol. Biol. Phys 2014;88(2):306–11. 
50. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation 
therapy and its impact on current and future clinical practice. J. Clin. Oncol 
2014;32(26). 
111 
 
51. Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT. Predictors 
of toxicity associated with stereotactic body radiation therapy to the central 
hepatobiliary tract. Int J Radiat Oncol 2015;91(5):986–94. 
52. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate 
to model high dose per fraction effects in radiosurgery. Semin. Radiat. Oncol 
2008;18(4):240–3. 
53. Song CW, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, Levitt SH. Radiobiology 
of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-
quadratic model. Int. J. Radiat. Oncol. Biol. Phys 2013;87(1):18–9. 
54. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. 
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. 
Radiat. Oncol. Biol. Phys 2015;53(4):810–21. 
55. Dawson La, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. 
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. 
Radiat. Oncol. Biol. Phys 2002;53(4):810–21. 
56. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for 
primary hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys 2011;81(4):447–
53. 
57. Eriguchi T, Takeda a, Oku Y, et al. Multi-institutional comparison of treatment 
planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma 
– benchmark for a prospective multi-institutional study. Radiat Oncol 2013;8:113, 
pii:1748-717X-8-113, doi:r10.1186/1748-717X-8-113. 
58. Sawrie SM, Fiveash JB, Caudell JJ. Stereotactic body radiation therapy for liver 
metastases and primary hepatocellular carcinoma: normal tissue tolerances and 
toxicity. Cancer Control 2010;17(2):111–9. 
59. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of 
primary liver cancer and hepatic metastases. Acta Oncol 2006;45(7):838–47. 
60. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar 
LE. A Phase I trial of stereotactic body radiation therapy (SBRT) for liver 
metastases. Int. J. Radiat. Oncol. Biol. Phys 2005;62(5):1371–8. 
112 
 
61. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized 
stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic 
cholangiocarcinoma. J. Clin. Oncol 2008;26(4):657–64. 
62. Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for 
unresectable cholangiocarcinoma. Radiother. Oncol 2010;94(1):47–52. 
63. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy 
of locally advanced pancreatic carcinoma. Radiother. Oncol 2005;76(1). 
64. Hoyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a 
review of evidence. Int. J. Radiat. Oncol. Biol. Phys 2012;82(3):1047–57. 
65. Bae SH, Kim M-S, Cho CK, et al. Predictor of severe gastroduodenal toxicity 
after stereotactic body radiotherapy for abdominopelvic malignancies. Int. J. Radiat. 
Oncol. Biol. Phys 2012;84(4):e469–74. 
66. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body 
radiation therapy for primary and metastatic liver tumors: a single institution phase 
I–II study. Acta Oncol 2006;45(7):831–7. 
67. Kirkpatrick JP, Kelsey CR, Palta M, et al. Stereotactic body radiotherapy: a 
critical review for nonradiation oncologists. Cancer 2014;120(7):942–54. 
68. Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after 
stereotactic body radiotherapy for malignant lesions of the lung and liver. Int. J. 
Radiat. Oncol. Biol. Phys 2011;80(3):692–7. 
69. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body 
radiotherapy of colorectal metastases. Acta Oncol (Madr) 2006;45(7):823–30. 
70. Mr Satvinder Mudan. LCA Hepato-pancreatobiliary Cancer Clinical   
Guidelines. November 2014. 
71. ICRU (International Commission on Radiation Units and Measurements) ICRU 
Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement 
to ICRU Report 50). Bethesda, MD: ICRU; 1999. 
72. Yukinori Matsuo, Hiroshi Onishi, Keiichi Nakagawa, Mitsuhiro Nakamura. 
Guidelines for respiratory motion management in radiation therapy.  J Radiat Res. 
2013 May; 54(3): 561–568. Published online 2012 Dec 13. doi: 10.1093/jrr/rrs122. 
113 
 
73. Japanese College of Radiology, Japanese Society for Therapeutic Radiology and 
Oncology, Japan Radiological Society. The 2008 Guidelines for Radiotherapy 
Planning. Higashi-matsuyama: Medical Kyoiku Kenkyusha, 2008 (in Japanese).  
74. Hansen AT, Petersen JB, Høyer M. Internal movement, set-up accuracy and 
margins for stereotactic body radiotherapy using a stereotactic body frame. Acta 
Oncol. 2006;45:948–952. 
75. Case RB, Sonke JJ, Moseley DJ, et al. Inter- and intrafraction variability in liver 
position in non-breath-hold stereotactic body radiotherapy. Int J Radiat Oncol Biol 
Phys. 2009;75:302–308. 
76. Heinzerling JH, Anderson JF, Papiez L, et al. Four-dimensional computed 
tomography scan analysis of tumor and organ motion at varying levels of abdominal 
compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol 
Phys. 
77. Hu Y, Zhou YK, Zeng ZC, et al. 4D-CT scans reveal reduced magnitude of 
respiratory liver motion achieved by different abdominal compression plate 
positions in patients with intrahepatic tumors undergoing helical tomotherapy. Med 
Phys. 2016;43:4335. 
78. Eccles CL, Dawson LA, Moseley JL, et al. Interfraction liver shape variability 
and impact on GTV position during liver stereotactic radiotherapy using abdominal 
compression. Int J Radiat Oncol Biol Phys. 2011;80:938–946. 
79. Eccles C, Brock KK, Bissonnette JP, et al: Reproducibility of liver position using 
active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol 
Phys 2006;64:751-759. 
80. Modern radiotherapy - Synergy Linear Accelerator - Image-Guided 
Radiotherapy. Synergy™XVI. http://www.medicaltk.com/en/products/synergy-
linear-accelerator-image-guided-radiotherapy-16.html. 
81. Clements M, Schupp N, Tattersall M, Brown A, Larson R. Monaco treatment 
planning system tools and optimization processes. Med Dosim. 2018;43(2):106‐117. 
doi:10.1016/j.meddos.2018.02.005. 
114 
 
82. Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. El papel de la dosis 
biológicamente efectiva (BED) en oncología clínica. Clin Oncol. 2001; 13 (2): 71–
81. 
83. Fowler JF. La fórmula lineal-cuadrática y el progreso en radioterapia 
fraccionada. Fr. J Radiol. 1989; 62 (740): 679–94. 
84. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for 
normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8 (11): 1981-97. Epub 
1982/11/01. 
85. D. A. Low, W. B. Harms, S. Mutic and J. A. Purdy, “A technique for the 
quantitative evaluation of dose distributions”, Medical Physics, 1998, 25, 656–661. 
86. Bases clínicas y anatómicas para la clasificación de las partes estructurales del 
hígado. Saulius Rutkauskas y col. Clínica de Radiología, Instituto de Anatomía, 
Clínica de Cirugía, Universidad de Medicina de Kaunas, Lituania. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
Appendix 1. 
 
Isodose curves shown on CT images (liver) 
 
The figures 16-20 below shows the DVH for each patient.  
 
 
Figure 17- DVH for the patient 1 
 
 
Figure 18- DVH for the patient 2 
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Figure 19- DVH for the patient 3 
 
 
Figure 20- DVH for the patient 4 
 
 
Figure 21- DVH for the patient 5 
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Appendix 2. 
 
Table 9 – DATA OF DVH FOR ALL 5 PATIENTS 
 
Patient Structure 
Volume 
(cm3) 
Min. 
Dose 
(Gy) 
Max. 
Dose 
(Gy) 
Mean. 
Dose 
(Gy) 
% 
in 
Volume 
% Vol 
< 
Cold 
Ref 
% Vol 
> 
Hot Ref 
 
 
 
 
 
1 
GTV 37.008 45.091 50.016 47.479 100.00 0.00 0.14 
PTV 102.098 40.188 50.016 46.769 100.00 1.73 0.05 
Liver 
Margin 
2183.910 0.080 47.271 8.827 100.00  16.85 
Lung S. 5098.790 0.050 48.868 2.360 99.46 - 4.90 
Spinal C 62.918 0.001 5.827 1.019 99.13 - - 
Kidney 
R 
246.558 0.019 0.569 0.147 100.00 - 0.00 
Heart 611.386 0.220 10.160 1.466 100.00 - - 
 
 
 
 
 
 
 
2 
GTV1 
GTV2 
GTV3 
2.859 
75.432 
4.140 
42.239 
38.215 
41.973 
44.501 
46.082 
45.241 
43.369 
43.439 
43.570 
100.00 
100.00 
100.00 
100.00 
99.04 
99.53 
0.00 
0.00 
0.00 
PTV 306.699 19.539 46.440 42.752 100.00 38.23 0.00 
Liver 
Margin 
1540.839 1.082 43.807 18.881 100.00 - 50.44 
Lung S. 4572.417 0.058 22.824 0.874 99.58 - 0.29 
Heart 622.395 0.596 41.452 4.111 100.00 - 2.04 
Spinal C. 112.557 0.075 14.463 2.142 99.73 - 0.00 
Kidney 
R 
224.064 0.381 20.649 3.753 100.00 - 42.10 
PTV1 17.958 37.258 44.828 42.747 100.00 39.68 0.00 
PTV2 258.396 19.814 46.440 42.839 100.00 35.40 - 
PTV3 22.437 33.082 46.056 42.422 100.00 6.48 0.00 
 
 
 
 
 
3 
GTV1 
GTV2 
4.872 
2.406 
45.768 
45.576 
48.500 
48.425 
46.939 
46.873 
100.00 
100.00 
0.00 
0.00 
0.00 
0.00 
PTV1 
PTV2 
28.428 
18.840 
37.287 
41.365 
48.966 
49.074 
46.548 
46.447 
100.00 
100.00 
1.20 
0.26 
0.00 
0.00 
Liver 
Margin 
1512.192 0.198 48.685 7.888 100.00 - 13.13 
Lung S 2918.076 0.018 48.520 0.494 99.33 - 0.44 
Spinal C. 82.920 0.019 7.246 1.389 99.51 - 0.00 
Kidney 
R 
124.914 0.544 48.241 9.779 100.00 - 24.58 
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Table 9 continuation 
 
 
 
 
 
4 
GTV1 
GTV2 
GTV3 
26.643 
8.136 
16.833 
38.571 
38.650 
38.246 
40.526 
40.446 
41.167 
39.490 
39.545 
39.707 
100.00 
100.00 
100.00 
0.01 
0.00 
0.25 
0.00 
0.00 
0.00 
PTV 177.972 32.734 41.167 39.292 100.00 1.75 0/00 
Liver 
Margin 
1377.012 0.118 40.582 12.250 100.00 - 21/95 
Kidney 
R 
113.208 0.105 3.408 0.458 100.00 - 0.10 
Lung S 3734.130 0.048 20.557 1.761 98.59 - 0.37 
Spinal C 45.030 0.025 10.391 2.136 99.53 - 0.00 
 
 
 
 
5 
GTV 32.370 39.864 48.239 42.260 100.00 0.01 2.15 
PTV 107.103 28.732 48.239 41.247 100.00 2.04 1.31 
Liver 
Margin 
1150.644 0.974 42.263 17.173 100.00 -  
Kidney 
R 
100.302 0.242 23.829 4.563 100.00 - 40.54 
Lung 2911.248 0.081 29.198 3.043 99.12 - - 
Spinal 
cord 
78.519 0.059 19.693 3.692 99.69 - 0.00 
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Appendix 3.  
 
ArcCHECK QA of Dose Distribution 
 
 
Figure 22- Patient 1 
 
 
          Figure 23- Patient 2 
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         Figure 24- Patient 3 
 
            
       Figure 25- Patient 4 
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Figure 26- Patient 5 
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Appendix 4. 
Table 11- CT / RMI of the abdominal cavities with contrasting dynamics 
 
 Patient 
Conclusions 
Data provided 2019 year Data provided 2020 year 
 
 
 
 
1 
09.10.2019 
Liver segment 7- as of 07/28/2018 negative 
dynamics in the form of an increase in total size by 
100%, changes in the nature of contrast gain. 
Liver segment 6- formation of fluid without gas 
probably a hemangioma. 
16.02.2020 
Segment 6 liver, probably 
hemangioma. For the period 
of 09/10/2019 - negative 
dynamics. Signs of distal 
obstruction of both ureters 
with the formation of 
hydronephrosis of both 
kidneys and ectasia of the 
ureters. Recommended: 
oncologist consultation, 
dynamic control of MRI in 
dynamics, ultrasound / MRI. 
 
 
 
 
 
 
2  
01.06.2019   
Liver segment 2, 3, 6 and 8 - solid formations in 
the liver. As of March 13, 2019 - stabilization of 
formations in the form of an increase in total size 
by a maximum of 8% (segment 2). 
- Choledochoectasia  
25.12.2019 
Segments 2, 3, 6 and 8 - solid formations in the 
liver - mts. As of 31.10.2019 progression in the 
form of an increase in non-target formations by a 
maximum of 40%. 
- Choledochoectasia 
 
 
 
 
 
 
Not yet done 
 
 
 
                                    - 
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3 
26.07.2019 
Liver segment 6- hypovascular liver formation 
Liver segment 7- cystic formation. 
Hepatomegaly, fatty hepatosis. 
05.12.2019   
Hepatic Mts (Liver segment 4), secondary damage 
of the abdominal lymph nodes - negative dynamic 
of 27.07.2019. 
Moderate hepatomegaly. Steatosis of the liver. 
 
 
 
 
Not yet done 
 
 
                                      - 
 
      
 
 
 
    
     4 
09.09.2019 
CT- In the liver parenchyma, hypodense lesions 
with weak peripheral accumulation of the contrast 
agent are determined: in liver segment 4a - the 
lesion 15x11x17 mm (previously 5x5 mm), in liver 
segment 8  - two discharge lesions with a total size 
of 34x30x44 mm (previously 30x20x27 mm), in 
liver segment 5 - lesions 31x36x30 mm (previously 
14x14x17 mm) and 13x10x11 mm (previously 
6x7x7 mm). The gates of the liver are 
differentiated, the portal vein is 12 mm. The 
hepatic veins are not dilated, their contours without 
features. Choledoch up to a diameter of 6. Bile 
ducts without filling defects, somewhat enlarged in 
the left lobe of the liver. 
 
 
 
 
 
 
 
Not yet done 
 
 
 
     5  
05.03.2019 
CT- The structure of the liver is disturbed due to 
multiple different-sized hyperactive focal changes, 
with fuzzy contours, diameters from 0.7 cm to 3.7 
* 3.3 cm, the largest: in liver segment 2- 1.3 cm, in 
liver segment 3- 3.3 * 3.6 cm, in liver segment 8-
1.4cm, in liver segment 5-2.0cm, in  liver segment 
7-2.5cm. 
 
 
Not yet done 
 
 
  
